

Special Section on The Opioid Crisis

Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence

Kelly E. Dunn, Andrew S. Huhn, Cecilia L. Bergeria, Cassandra D. Gipson, and Elise M. Weerts

Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland (K.D.E., A.S.H., C.L.B., E.M.W.); and Arizona State University, Tempe, Arizona (C.D.G.)

Received March 8, 2019; accepted July 30, 2019

ABSTRACT

Opioid misuse and abuse is a major international public health issue. Opioid use disorder (OUD) is largely maintained by a desire to suppress aversive opioid withdrawal symptoms. Opioid withdrawal in patients seeking abstinence from illicit or prescribed opioids is often managed by provision of a μ -opioid agonist/partial agonist in combination with concomitant medications. Concomitant medications are administered based on their ability to treat specific symptoms rather than a mechanistic understanding of the opioid withdrawal syndrome; however, their use has not been statistically associated with improved treatment outcomes. Understanding the central and/or peripheral mechanisms that underlie individual withdrawal symptom expression in humans will help promote medication development for opioid withdrawal management. To support focused

examination of mechanistically supported concomitant medications, this review summarizes evidence from preclinical ($N = 68$) and human ($N = 30$) studies that administered drugs acting on the dopamine, serotonin, cannabinoid, orexin/hypocretin, and glutamate systems and reported outcomes related to opioid withdrawal. These studies provide evidence that each of these systems contribute to opioid withdrawal severity. The Food and Drug Administration has approved medications acting on these respective systems for other indications and research in this area could support the repurposing of these medications to enhance opioid withdrawal treatment. These data support a focused examination of mechanistically informed concomitant medications to help reduce opioid withdrawal severity and enhance the continuum of care available for persons with OUD.

Introduction

The increased prevalence of opioid use disorder (OUD) and opioid-related morbidity and mortality is a national and international public health crisis. Continuous opioid exposure results in physiologic dependence and a prominent and aversive opioid withdrawal syndrome upon opioid discontinuation. As shown in Fig. 1, opioid withdrawal manifests as an acute syndrome that begins within hours of the final dose and can last for up to 14 days, and is followed by a protracted syndrome that can persist for several additional weeks (Martin and Jasinski, 1969; Jasinski, 1981). Opioid withdrawal symptoms vary in severity and expression across individuals and

continued opioid use and opioid relapse in persons with OUD are driven, in part, by a goal of avoiding opioid withdrawal symptoms and associated cravings (Hutcheson et al., 2001; Negus and Banks, 2018). As a result, OUD pharmacotherapies frequently aim to suppress symptoms of acute opioid withdrawal, an approach first reported in 1949 (Powers, 1949) and validated in 1965 (Dole and Nyswander, 1965).

The current standard-of-care treatment of opioid withdrawal management is to administer methadone or buprenorphine, which act as full or partial agonists on the μ -opioid receptor, respectively (Gowing et al., 2016). Both medications suppress symptoms of withdrawal when administered chronically; however, symptoms reemerge when doses are tapered down, which occurs when patients are withdrawn from opioids they have been using illicitly or as prescribed to them for pain management (Farrell, 1994). Several concomitant medications are commonly administered to manage emergent symptoms of acute withdrawal (Hillhouse et al., 2010; Dunn et al., 2011; Schuckit, 2016). These include nonsteroidal anti-inflammatory

Salary support for this review was provided by the National Institutes of Health National Institute on Drug Abuse [Grants R01DA042751, R01DA035246, R01DA040644, and R34DA042926 (to K.E.D.); UG3DA048734 (to A.S.H. and K.E.D.); and R21DA044479, R03DA045881, and R00DA036569 (to C.D.G.)], and the Arizona Alzheimer's Consortium (to C.D.G.).
<https://doi.org/10.1124/jpet.119.258004>.

ABBREVIATIONS: CB₁, cannabinoid type 1 receptor; DA, dopamine; FDA, Food and Drug Administration; 5-HT, serotonin; iGlu, ionotropic glutamate; mGlu, metabotropic glutamate; OUD, opioid use disorder; OX, orexin; THC, tetrahydrocannabinol.




Fig. 1. Schematic of the human opioid withdrawal syndrome. The prototypical human opioid withdrawal curve is shown here for both the acute (gray) and protracted (dashed line) phases. Although the specific duration and magnitude of withdrawal varies across individuals, the acute withdrawal syndrome generally begins 4–6 (short acting) and 24–36 (long acting) hours after opioid discontinuation, peaks within 2 to 3 (short acting) and 3–7 (long acting) days, and ends within 5–7 (short acting) and 7–14 (long acting) days, as indicated by the vertical lines. Although specific symptoms emerge at different times for different individuals, an expected symptom progression is indicated in the brackets across the top of the figure; the ends of the brackets signify when the clusters of specific symptoms generally emerge and dissipate. Protracted withdrawal is hypothesized to extend for an additional 1–4 weeks following resolution of the acute withdrawal syndrome. Note: additional symptoms may exist that are not included here.

drugs for muscle aches and pains, promethazine for nausea/vomiting, loperamide for diarrhea, and clonidine or trazodone for sleep disturbance. The use of these medications is based on their perceived effectiveness for individual symptoms rather than a mechanistic understanding of the opioid withdrawal syndrome or empirical evidence of their efficacy in reducing opioid withdrawal severity. The only retrospective evaluation conducted on this topic reported no significant association between these medications and opioid withdrawal outcomes (Hillhouse et al., 2010).

The exceptions to this are two adrenergic agonists. The first is clonidine, which is prescribed off-label (Gold et al., 1978), and the second is lofexidine (Lucemyra), which was approved by the Food and Drug Administration (FDA) for opioid withdrawal in 2018 (Gorodetzky et al., 2017). Administration of clonidine and lofexidine is premised upon a mechanistic understanding that the adrenergic system modulates some opioid withdrawal symptoms through locus coeruleus-mediated noradrenergic hyperactivity (Gold et al., 1979; van Dongen, 1981). The majority of research examining adrenergic agonist withdrawal suppression has focused on clonidine, and there is strong evidence that clonidine reliably suppresses some symptoms of opioid withdrawal while concurrently increasing the severity of other symptoms (Gianutos et al., 1976; Schulz and Herz, 1977; Bednarczyk and Vetulani, 1978). The net result is that clonidine produces mild-to-moderate opioid withdrawal suppression (Gowing et al., 2016), the degree to which varies across individuals (Dunn et al., 2018b).

Despite the fact that OUD treatment is largely organized around the provision of pharmacotherapy to manage opioid withdrawal, concomitant medications are not selected based on a mechanistic understanding of the central and/or peripheral systems underlying individual opioid withdrawal symptom expression in humans. This review summarizes preclinical animal and human evidence that the dopamine (DA), serotonin (5-HT), cannabinoid, orexin/hypocretin, and glutamate neurotransmitter systems directly contribute to the expression and/or severity of specific opioid withdrawal symptoms. These systems were selected for review because of the body of literature supporting their pivotal involvement in the opioid withdrawal syndrome and the fact that several FDA-approved or investigational medications that act on these systems exist and could be evaluated and ultimately repurposed for an opioid withdrawal indication. The expectation is not that these medications would be used in lieu of opioid

agonists but that they would be administered in combination with opioid agonist therapy to replace the aforementioned symptomatic medications and improve opioid withdrawal management. The norepinephrine system is not discussed here because lofexidine has gained recent FDA approval and the GABA system was omitted because the majority of FDA-approved medications acting on that system have prominent abuse liability profiles that limit their adoption in OUD treatment settings. The overarching goal of this review is to provide a resource to support the prospective examination of candidate concomitant medications for opioid withdrawal symptom management.

Materials and Methods

This review reports the results of studies that described opioid withdrawal symptom incidence and/or severity following exposure to agents acting on the aforementioned systems. As shown in Table 1, there is generally good concordance for a number of opioid withdrawal symptom categories between animal and human models of opioid withdrawal, although the expression of symptoms within each category is often species specific. Withdrawal in rodents generally includes increased jumping, self-directed behaviors (increased grooming and penile licking), hyperactivity (locomotion, digging, and rears), vocalization, ptosis, wet dog shakes, teeth chattering, secretions (lacrimation, rhinorrhea, and salivation), respiration, and gastrointestinal motility (increased defecation and loose stools/diarrhea). Human withdrawal expression is comprised of several symptoms (as indicated in Fig. 1; Table 1) that vary across individuals with regard to incidence and severity; no demographic or drug use characteristics have been identified that reliably predict the severity of human opioid withdrawal symptoms. An exception to this is gender, for which there is substantial preclinical evidence to support causal associations between gonadal hormones and opioid effects (Huhn et al., 2018), and some limited human empirical evidence that gender may moderate withdrawal severity (Dunn et al., 2018b).

Reviewed papers were identified through PubMed searches inclusive of all years using the following search terms: opioid, opiate, withdrawal AND dopamine, serotonin, 5-HT, cannabinoid, cannabis, THC, orexin, hypocretin, and glutamate (where THC denotes tetrahydrocannabinol). Eligible studies included outcome data about the opioid withdrawal syndrome and were conducted in rodents, non-human primates, or humans with opioid physical dependence and administered an agent that acted on one or more of the systems of interest. A total of 68 preclinical and 30 human studies were identified and reviewed. Preclinical studies examined withdrawal in animals with opioid physical dependence either by administering an opioid antagonist (in a precipitated withdrawal model) or through abrupt opioid discontinuation (in a spontaneous withdrawal model). Since only

TABLE 1

Withdrawal systems and symptoms conserved across species

Only symptoms for which there is correspondence across species are presented; additional symptoms exist that are species specific but are not included here.

| Withdrawal System and Symptoms | Human | Rat | Mouse |
|--|-------|-----|-------|
| Anhedonia | | | |
| Brain stimulation threshold | | X | X |
| Conditioned aversion | | X | X |
| Depression | X | | |
| Anxiety/escape behaviors (rodents) | | | |
| Anxiety | X | | |
| Burrowing | | X | X |
| Digging | | X | X |
| Jumping | | X | X |
| Rearing | | X | X |
| Changes in body temperature | | | |
| Hot and/or cold flashes | X | | |
| Hypothermia | | X | X |
| Piloerection (gooseflesh) | X | X | X |
| Teeth chattering | | X | X |
| Gastrointestinal | | | |
| Defecation | | X | X |
| Diarrhea, Loose stool | X | X | X |
| Nausea | X | | |
| Vomiting | X | | |
| Hyperactivity, self-directed behaviors | | | |
| Chewing | | X | X |
| Grooming | | X | X |
| Licking | | X | X |
| Locomotion | X | X | X |
| Penile licking | | X | X |
| Restlessness | X | | |
| Motivation to use | | | |
| Craving | X | | |
| Progressive ratio breakpoint | X | X | X |
| Reinstatement | | X | X |
| Pain, hyperalgesia | | | |
| Joint aches and pains | X | | |
| Muscle aches and pains | X | | |
| Reactive to touch | | X | X |
| Ultrasonic vocalizations | | X | X |
| Writhing | | X | X |
| Ptosis | | X | X |
| Secretions | | | |
| Lacrimation | X | X | X |
| Rhinorrhea | X | X | X |
| Salivation | | X | X |
| Urination | | X | X |
| Tremors/shaking | | | |
| Facial tremor | | X | X |
| Forepaw tremors | | X | X |
| Hand tremors | X | | |
| Head shakes | | X | X |
| Limb shakes | | X | X |
| Wet dog shakes | | X | X |

a limited number of human empirical studies ($n = 16$) were available for this review, case reports ($n = 7$), retrospective chart reviews ($n = 3$), a prospective cohort study ($n = 1$), an online survey or quality-assurance surveys ($n = 2$), and a secondary outcome analysis ($n = 1$) were included to provide breadth of coverage. All of the results discussed subsequently refer to opioid withdrawal symptoms that were observed during the acute (vs. protracted) opioid withdrawal. Specific study details are provided in accompanying tables, which have been organized into preclinical tables for dopamine (Table 2), serotonin (Table 3), cannabinoids (Table 4), orexin (Table 5), glutamate (Table 6), and medications acting on multiple systems (Table 7), and human tables categorized as empirical (Table 8) and nonempirical (Table 9) reports.

Results

Dopamine System

Dopamine neurotransmission occurs via two families of G protein-coupled receptor families, the D_1 -like receptors that

include D_1 and D_5 receptor subtypes, and the D_2 -like receptors that include D_2 , D_3 , and D_4 receptor subtypes. DA is frequently implicated in substance use disorders (for a review, see Volkow et al., 2017) and there is clear evidence of clinically meaningful DA and opioid interaction in humans. For instance, many methadone patients begin using cocaine during methadone maintenance (Leri et al., 2003) and methadone has been shown empirically to increase the reinforcing effects of cocaine (Preston et al., 1996). The following section reviews only preclinical research because no human studies met the inclusion criteria.

Preclinical Withdrawal. Preclinical behavioral evidence clearly implicates DA in the expression of opioid withdrawal, and drugs acting on this system often exert positive effects at one dose and negative effects at another dose. Drugs that increase DA, including the DA transport reuptake inhibitors amphetamine and cocaine and the DA precursor L-DOPA,

TABLE 2
Preclinical examinations of the dopamine system on the opioid withdrawal syndrome
Only results pertaining to effects of non-opioid drugs on opioid withdrawal symptoms are presented.

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|---------------------------|---|---------|-------------|--|---|---|---|
| Ary and Lomax (1976) | Apomorphine (20 μ g); Dopamine (10, 50, 100, and 200 μ g); Pimozide (0.5 and 1 μ g, i.p.). Administered to rostral hypothalamus and lateral ventricle unless indicated. | Rat | ≥ 5 | Precipitated, naloxone (1 mg/kg; i.p.) on day 3 | Morphine (75 mg) subcutaneous implant | Body temperature | Rostral hypothalamus injections: apomorphine (D ₂ agonist; 20 μ g) increased the hypothermia produced by naloxone, pimozide (D ₂ antagonist; 0.5 and 1 μ g) and dopamine had no effect. Lateral ventricle injections: no effects on naloxone-induced hypothermia. |
| Cox et al. (1976) | Apomorphine (1.25 mg/kg) and pimozide (0.5 mg/kg) administered intraperitoneally; pimozide (0.5 μ g) administered intracerebroventricularly. | Rat | NR | Precipitated, naloxone (1 mg/kg; i.p.) on day 3 | Morphine (75 mg) subcutaneous implant | Body temperature, chewing, diarrhea, head shakes, facial tremor, grooming, licking, sneezing, teeth chatter, wet dog shakes, and writhing. Total withdrawal score | Apomorphine (D ₂ agonist) (1.25 mg/kg, i.p.) decreased chewing, teeth chattering, wet dog shakes, and writhing. Pimozide (D ₂ antagonist) (0.5 mg/kg, i.p.) reduced hypothermia and increased chewing, head shakes, and writhing. |
| el-Kadi and Sharif (1998) | Apomorphine (0.5, 1, 2.5, 5, 10, 20, and 30 mg/kg); L-DOPA (100 and 500 mg/kg); haloperidol (0.2 and 1.0 mg/kg); pimozide (2 and 5 mg/kg); domperidone (5 and 10 mg/kg); flupenthixol (0.05 and 0.1 mg/kg); sulpride (5 mg/kg). Administered intraperitoneally. | Mouse | 8–10 | Precipitated, naloxone (1 mg/kg; i.p.) on day 7 | Escalating morphine doses up to 160 mg/kg, s.c., by day 6 | Body temperature, body weight, burrows, jumping, and wet dog shakes | Intracerebroventricularly: pimozide (0.5 μ g, i.p.) significantly blocked hypothermia. L-DOPA (dopamine precursor) (100 and 500 mg/kg) reduced jumping, burrows, body weight loss, hypothermia (100 and 500 mg/kg), and wet dog shakes (500 mg/kg). Apomorphine (D ₂ agonist) increased burrows and jumping at low doses (2.5 and 5 mg/kg) and decreased them at high doses (10, 20, and 30 mg/kg). Apomorphine also decreased body weight loss (2.5, 5, and 10 mg/kg) and increased wet dog shakes (2.5, 5, 10, and 20 mg/kg) and hypothermia (all doses). Haloperidol (D ₂ antagonist) reduced jumps (0.2 and 1 mg/kg), wet dog shakes (0.2 and 1 mg/kg), burrows (0.2 and 1 mg/kg), and body weight loss (1 mg/kg). Pimozide (D ₂ antagonist) decreased jumps (2 and 5 mg/kg), and wet dog shakes, burrows, and body weight loss (5 mg/kg). Domperidone (D ₂ antagonist) decreased jumping and hypothermia (10 mg/kg) but increased body weight loss (10 mg/kg). Flupenthixol (D ₂ antagonist) decreased wet dog shakes and burrows (0.05 and 0.1 mg/kg), and jumping, body weight loss, and hypothermia (0.1 mg/kg). Sulpride (D ₂ agonist) (5 mg/kg) increased all symptoms. |
| Herz et al. (1974) | d-Amphetamine (0.5, 1, 2, and 5 mg/kg); cocaine (5, 10, and 25 mg/kg); L-DOPA (100 mg/kg); apomorphine (1, 2.5, and 5 mg/kg); desipramine (2.5, 5, and 10 mg/kg). Administered intraperitoneally. | Rat | 8–16 | Precipitated, levallorphan (1 mg/kg; i.p.) on day 10 | Morphine subcutaneous implant (dose NR), six pellets implanted over 10 days | Eye twitching, diarrhea, flying, jumping, lacrimation, ptosis, rhinorrhea, salivation, teeth chattering, wet dog shakes, and writhing | d-Amphetamine increased jumping (0.5 and 1, 2 mg/kg) and teeth chattering (1 mg/kg), and decreased wet dog shakes (0.5 and 1 mg/kg). All signs decreased at 2 and 5 mg/kg. Cocaine increased jumping (10 mg/kg) and decreased wet dog shakes (10 mg/kg). All signs decreased at 25 mg/kg. L-DOPA (dopamine precursor) decreased ptosis and diarrhea (100 mg/kg) but increased eye twitching (100 mg/kg). |

(continued)

TABLE 2—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|-----------|---|---------|-------------|-------------------|-------------------|---------------------------|---|
| | | | | | | | Apomorphine (D ₂ agonist) decreased ptosis and increased eye twitching at 1 mg/kg, increased ptosis and decreased diarrhea at 2.5 mg/kg, and decreased ptosis and diarrhea but increased eye twitching at 5 mg/kg. Desipramine decreased ptosis and diarrhea but increased eye twitching at all doses, and increased jumping at 5, 10, and 20 mg/kg. |

NR, not reported.

dose dependently increase several symptoms while simultaneously decreasing others (Herz et al., 1974; el-Kadi and Sharif, 1998). Numerous studies have reported that low doses of the D₂ agonist apomorphine exacerbates withdrawal, evidenced by increased jumping, wet dog shakes, burrows, and hyperthermia, whereas higher doses decrease jumping, burrowing, and other responses (Herz et al., 1974; Ary and Lomax, 1976; Cox et al., 1976; el-Kadi and Sharif, 1998). The D₂ receptor antagonists domperidone, flunitroflanzol, and pimozide also reduce several opioid withdrawal symptoms, whereas the D₂ receptor agonist sulpride increased the severity of all symptoms measured (Cox et al., 1976; el-Kadi and Sharif, 1998).

Serotonin System

Extracellular levels of serotonin are moderated by the membrane protein 5-HT transporter, and with the exception of the ionotropic 5-HT₃ receptor, 5-HT exerts effects through seven families of G protein-coupled receptors (5-HT₁₋₇) with ≥14 subtypes (for a review, see Berger et al., 2009). A large number of commercially available medications act on the 5-HT system and could be evaluated for OUD withdrawal management. For instance, tricyclic medications that inhibit 5-HT reuptake are recommended and widely used for pain management (Finnerup et al., 2015; Obata, 2017). Several 5-HT medications are also formally approved for mood disturbance and anxiety, two prominent opioid withdrawal symptoms that are present during both the acute and protracted withdrawal phases (Handelsman et al., 1987; Latowsky, 1996; Wesson and Ling, 2003). Intracerebroventricular injections of 5-HT to non-dependent rats have also been observed to directly and dose dependently produce wet dog shakes (Drust et al., 1979), which is a prominent sign of opioid withdrawal in rodents.

Preclinical Withdrawal. Similar to DA, the 5-HT system can both increase and decrease the severity of withdrawal symptoms depending on the dose of drug administered; for instance, administration of the antidepressant fenfluramine, which promotes 5-HT release and inhibits 5-HT reuptake, decreased jumping (Cervo et al., 1981; Romandini et al., 1984) but not wet dog shakes or other symptoms (Romandini et al., 1984). The 5-HT₂ receptor agonists meta-chlorophenylpiperazine and lorcaserin also decreased jumping (Samanin et al., 1980; Cervo et al., 1981; Shahidi and Hashemi-Firouzi, 2014; Wu et al., 2015) as well as diarrhea (Samanin et al., 1980) and paw licking (Shahidi and Hashemi-Firouzi, 2014), although another study found that lorcaserin only reduced wet dog shakes, paw licking, and penile grooming but not jumping or other withdrawal signs (Zhang et al., 2016). The 5-HT_{2A/B} receptor agonist quipazine selectively decreased jumping but did not decrease other signs of opioid withdrawal (Samanin et al., 1980) and the 5-HT₇ receptor agonist AS19 has been observed to block jumping, grooming, shaking, teeth chattering, and writhing (Shahidi and Hashemi-Firouzi, 2014).

Similar to agonists of 5-HT receptors, antagonists also block some withdrawal behaviors while exacerbating others. For example, pretreatment with the 5-HT₂ antagonist cyproheptadine and the mixed 5HT₂ antagonist/5HT₁ agonist methysergide reduced jumping, wet dog shakes, and burrows but increased weight loss and hypothermia (el-Kadi and Sharif, 1995). The 5-HT₃ antagonist ondansetron reduced jumping, defecation, and wet dog shakes in one study (Pinelli et al., 1997) but had no effect on wet dog shakes, paw shakes, or

TABLE 3

Preclinical examinations of the serotonin system on the opioid withdrawal syndrome

Only results pertaining to effects of non-opioid drugs on opioid withdrawal symptoms are presented.

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|---------------------------|---|---------|-------------|--|---|---|---|
| Cervo et al. (1981) | d-fenfluramine (5 mg/kg), cyproheptadine HCL (10 mg/kg), clonidine (0.1 mg/kg), phentolamine methane sulphonate (5 mg/kg), piperoxane HCL (5, 10 mg/kg), phenoxybenzamine HCL (20 mg/kg), prazosin HCL (10 mg/kg), propranolol (10 mg/kg), haloperidol (1 mg/kg), piritidil monometane sulphonate (60 mg/kg). Administered intraperitoneally. | Rat | ≥18 | Precipitated, naloxone (1 mg/kg, i.p.) on day 11 | Escalating morphine (route NR) doses up to 160 mg/kg by day 7 | Diarrhea, flat posture, jumping, ptosis, salivation, teeth chattering, vocalization on touch, and wet dog shakes | d-fenfluramine (SSRI) reduced jumping only. Clonidine (α_2 agonist) reduced diarrhea and ptosis. Phenoxybenzamine (adrenergic antagonist) reduced diarrhea. The adrenergic antagonists piperoxane, phentolamine methane sulphonate, prazosin (α_1), propranolol (β_1), haloperidol, and piritidil monometane sulphonate (α_2) had no effects. |
| el-Kadi and Sharif (1995) | Cyproheptadine (0.5, 1, 5, and 10 mg/kg), methysergide (0.1, 1, 3, and 6 mg/kg). Administered intraperitoneally. | Mouse | 8–10 | Precipitated, naloxone (1 mg/kg, i.p.) on day 7 | Escalating morphine doses up to 160 mg/kg, s.c., by day 6 | Body temperature, body weight, burrowing, jumping, and wet dog shakes | Cyproheptadine (5-HT _{2A,2C} antagonist) increased jumping (0.5 and 1 mg/kg) and hypothermia (all doses) and decreased jumping (5 and 10 mg/kg), wet dog shakes (all doses), burrows (10 mg/kg), and body weight loss (5 and 10 mg/kg). Methysergide (5-HT ₂ antagonist and 5-HT _{1A} agonist) decreased burrowing, jumping, and wet dog shakes (all doses), and body weight loss (1, 3, and 6 mg/kg) but increased hypothermia (1, 3, and 6 mg/kg). |
| Higgins et al. (1991) | Ondansetron (0.01, 0.1, and 1 mg/kg), MDL 7222 (1 and 3 mg/kg). Administered subcutaneously. | Rat | 6 | Precipitated, naloxone (0.5 mg/kg, s.c.) on days 3 and 4 | Morphine (75 mg) subcutaneous implant | Body temperature, paw shakes, mouth movements, salivation, startle, rhinorrhea, penile grooming, teeth chattering, weight loss, and wet dog shakes | Ondansetron (5-HT ₃ antagonist) attenuated body weight loss (0.1 and 1 mg/kg). MDL 7222 (5-HT ₃ antagonist) also attenuated body weight loss (3 mg/kg). |
| Pang et al. (2016) | Glemanserin (0.5 mg/kg). Administered intraperitoneally. | Mouse | 10 | Precipitated, naloxone (5 mg/kg, i.p.) on day 7 | Escalating morphine doses up to 100 mg/kg, s.c., by day 6 | Body grooming, burrowing, digging body, extended posture, face grooming, head shakes, jumping, paw licking, penile licking, rearing, scratching, and wet dog shakes | Glemanserin (5-HT _{2A} antagonist) decreased jumping (0.5 mg/kg). |
| Pinelli et al. (1997) | Ondansetron (0, 1, 2, and 4 mg/kg). Administered intraperitoneally. | Rat | 8 | Precipitated, naloxone (30 mg/kg, i.p.) on day 4 | Escalating morphine doses up to 100 mg/kg, i.p., by day 4 | Body temperature, defecation, jumping, salivation, urine excretion, and wet dog shakes | Ondansetron (5-HT ₃ antagonist) reduced defecation (1, 2, and 4 mg/kg), body temperature (4 mg/kg), and jumping (2 and 4 mg/kg), but increased wet dog |

(continued)

TABLE 3—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|------------------------------------|---|---------|-------------|---|---|---|--|
| Romandini et al. (1984) | (+)-Fenfluramine (5 mg/kg); m-chlorophenylpiperazine (CPP; 2.5 mg/kg), Clonidine (0.5 mg/kg). Administered intraperitoneally. | Rat | ≥16 | Precipitated, naloxone (1 mg/kg, i.p.). Experiment 1 tested on Day 3; Experiment 2 on Day 5 | Experiment 1: Morphine (75 mg) subcutaneous implant; Experiment 2: Escalating morphine doses up to 40 mg/kg, i.p., by day 5 | Abnormal posture, diarrhea, jumping, ptosis, salivation, teeth chattering, vocalization on touch, wet dog shakes | shakes (1, 2, and 4 mg/kg). (–)-fenfluramine (SSRI) and m-CPP (5-HT agonist) decreased jumping. Clonidine (α_2 agonist) reduced wet dog shakes and increased jumping. |
| Samanin et al. (1980) | Quipazine (5 mg/kg), m-CPP (2.5 mg/kg), clonidine (0.5 mg/kg), haloperidol (0.5 mg/kg), propranolol hydrochloride (10 mg/kg). Administered intraperitoneally. | Rat | NR | Precipitated, naloxone (1 mg/kg, i.p.) on day 11 | Escalating morphine doses up to 160 mg/kg, s.c., by day 7 | Diarrhea, dyspnea, flat posture, jumping, ptosis, teeth chattering, salivation, vocalization on touch, and wet dog shakes | m-CPP (5-HT _{2C} agonist) decreased diarrhea and jumping. Quipazine (5-HT _{2A/3} agonist) decreased jumping. Clonidine (α_2 agonist) decreased diarrhea and ptosis. Propranolol and haloperidol had no effect. |
| Shahidi and Hashemi-Firouzi (2014) | AS19 (3, 5, and 10 mg/kg); SB269970 (1, 3, and 10 mg/kg). Administered intraperitoneally. | Mouse | 8 | Precipitated, naloxone (3 mg/kg, s.c.) on day 5 | Escalating morphine doses up to 45 mg/kg, s.c., by day 5 | Body grooming, body weight, face grooming, head shakes, jumping, limb shakes, sniffing, standing, teeth chattering, and writhing | AS19 (5-HT ₇ agonist) decreased weight loss (all doses); jumping, head shaking, standing, and writhing (5 and 10 mg/kg); and teeth chattering and limb shaking (10 mg/kg). SB269970 (5-HT _{7A} antagonist) increased teeth chattering (10 mg/kg) and limb shaking (1 mg/kg). |
| Wu et al. (2015) | Lorcaserin (0.5 mg/kg), clonidine (0.05 mg/kg). Administered intraperitoneally. | Mouse | 10 | Precipitated, naloxone (5 mg/kg, i.p.) on day 5 | Escalating diacetyl morphine doses up to 50 mg/kg, s.c., by day 5 | Body grooming, burrowing, digging body, extended posture, head shakes, jumping, paw licking, penile grooming, rearing, and wet dog shakes | Lorcaserin (5-HT _{2C} agonist) decreased jumping and paw licking. Clonidine (α_2 agonist) decreased jumping and paw licking. |
| Zhang et al. (2016) | Lorcaserin (0.5, 0.75, and 1.0 mg/kg), SB242084 (1.0 mg/kg), Clonidine (0.2 mg/kg). Administered intraperitoneally. | Mouse | 9 to 10 | Precipitated, naloxone (5 mg/kg, i.p.) on day 7 | Escalating morphine doses up to 100 mg/kg, s.c., by day 6 | Body grooming, burrowing, defecation, digging body, extended posture, face grooming, head shakes, jumping, paw licking, penile licking, piloerection, ptosis, rearing, scratching, urination, vocalization on touch, and wet dog shakes | Lorcaserin (5-HT _{2C} agonist) decreased jumping, burrowing, body grooming, rearing, wet dog shakes, paw licking, penile licking, and scratching (all doses). Clonidine (α_2 agonist) decreased jumping, burrowing, body grooming, rearing, wet dog shakes, head shakes, paw licking, penile licking, and scratching (0.2 mg/kg). SB242084 (5-HT _{2C} antagonist; 0.2 mg/kg) pretreatment blocked lorcaserin (0.5 mg/kg) suppression of jumping. |

m-CPP, meta-chlorophenylpiperazine; SSRI, selective serotonin reuptake inhibitor; NR, not reported.

TABLE 4

Preclinical examinations of the cannabis system on the opioid withdrawal syndrome

Only results pertaining to effects of non-opioid drugs on opioid withdrawal symptoms are presented.

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Doses and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|----------------------------|---|---------|-------------|--|---|---|---|
| Bhargava (1976) | THC (2.5, 5, and 10 mg/kg). Administered intraperitoneally. | Mouse | NR | Precipitated, naloxone (30 mg/kg, s.c.) on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Defecation, jumping, and rearing | THC (all doses) decreased defecation, jumping, and rearing. |
| Cichewicz and Welch (2003) | THC (0, 20, and 50 mg/kg). Administered orally. | Mouse | 6 | Precipitated, naloxone (1 mg/kg, s.c.) 12 hours after final morphine dose | Escalating morphine (oral) doses up to 300 mg/kg by day 7 | Diarrhea and jumping | THC (all doses reduced jumping. |
| Del Arco et al. (2002) | AM404 (2 and 10 mg/kg). Administered intraperitoneally. | Mouse | 8–10 | Precipitated, naloxone (1 mg/kg, route NR) on day 6; spontaneous withdrawal on day 6, 7, 8, or 9 | Escalating morphine doses up to 100 mg/kg, i.p., by day 5 | Abdominal constrictions, body weight, jumping, locomotor activity, piloerection, swallowing movements, and wet dog shakes | AM404 (anandamide transport inhibitor) had no effect on naloxone-precipitated withdrawal. AM404 decreased spontaneous withdrawal signs of jumping (all doses) and locomotor activity (10 mg/kg). |
| Gamage et al. (2015) | THC (1, 3, and 10 mg/kg), JZL184 (4 and 40 mg/kg), PF-3845 (1, 3, and 10 mg/kg), and SA-57 (1.25, 5, and 12.5 mg/kg). JZL184, PF-3845, and SA-57 administered intraperitoneally; THC administered subcutaneously. | Mouse | 16–28 | Precipitated, naloxone (0.3, 1 mg/kg, s.c.) on day 2 | Morphine (75 mg) subcutaneous implant for 2 days | Diarrhea, head shakes, jumping, and paw tremors | THC (3 and 10 mg/kg), JZL184 (MAGL inhibitor; 40 mg/kg), SA-57 (dual FAAH/MAGL inhibitor; 5 and 12.5 mg/kg) decreased jumping. PF-3845 (FAAH inhibitor) had no effect. |
| Hine et al. (1975a) | THC (1, 2, 5, and 10 mg/kg). Administered intraperitoneally. | Rat | 7 | Precipitated, naloxone (4 mg/kg, i.p.) on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Abnormal posture, chewing, defecation, diarrhea, ear blanching, ptosis, teeth chattering, vocalization, wet dog shakes, and total withdrawal score | THC (5 and 10 mg/kg) reduced total withdrawal scores, defecation, diarrhea, and wet dog shakes. |
| Hine et al. (1975b) | Groups 1 and 2: THC (1 mg/kg). Group 3: THC (10 mg/kg). Administered intraperitoneally. | Rat | 8–11 | Precipitated, naloxone (4 mg/kg, i.p.) on day 13 (group 1) or day 26 (groups 2 and 3) | Group 1: daily methadone injections (10 mg/kg, s.c.) for 13 days. Groups 2 and 3: daily methadone injections (up to 30 mg/kg, s.c.) for 26 days | Abnormal posture, body temperature, chewing, defecation, ear blanching, escapes, ptosis teeth chattering turning, vocalization on touch, wet dog shakes, and total withdrawal score | THC (1 mg/kg) decreased defecation, diarrhea, ear blanching, vocalization on touch, and total withdrawal score in animals in group 1 who received 13 days of methadone exposure. THC (10 mg/kg) decreased defecation, diarrhea, escapes, turns, wet dog shakes, and total withdrawal score in group 3 who received 26 days of methadone exposure. |
| Hine et al. (1975c) | THC (2 mg/kg), cannabidiol (10 mg/kg), | Rat | 8–9 | Precipitated, naloxone | Morphine (75 mg) subcutaneous | Abnormal posture, audible grinding, | THC (2 mg/kg) decreased total |

(continued)

TABLE 4—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Doses and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|-------------------------|--|---------|-------------|--|--|--|--|
| | THC (2 mg/kg) + cannabidiol (10 mg/kg). Administered intraperitoneally. | | | (4 mg/kg, i.p.) on day 3 | implant for 3 days | chewing, defecation, escapes, diarrhea, ear blanching, ptosis, teeth chattering, vocalization on touch, wet dog shakes, and writhing | withdrawal scores, defecation, and diarrhea. Cannabidiol alone had no effect. THC (2 mg/kg) + cannabidiol (10 mg/kg) decreased total withdrawal scores, defecation, ear blanching, escapes, and wet dog shakes. |
| Li et al. (2019) | AM1710 (5 mg/kg). Administered intraperitoneally. | Mouse | 8 | Precipitated, naloxone (5 mg/kg, i.p.) after final morphine dose | Daily morphine injections (10 mg/kg, i.p.) for 12 days | Body temperature, body weight, and jumping | AM1710 (CB ₂ agonist; 5 mg/kg) decreased jumping. |
| Lichtman et al. (2001) | THC (0, 0.1, 0.3, 1, 3, and 10 mg/kg). Administered subcutaneously. | Mouse | 6 | Precipitated, naloxone (1 mg/kg, i.p.) on day 5 | Morphine (75 mg) subcutaneous implant for 5 days | Diarrhea, head shake, jumping, paw tremor, ptosis, scratching, and writhing | THC dose dependently reduced head shakes and paw tremors (specific doses that produced effects NR). |
| Mas-Nieto et al. (2001) | Rimonabant (10 mg/kg), rimonabant (10 mg/kg) + morphine (dose escalated to 100 mg/kg by day 5). Administered intraperitoneally. | Mouse | 7–10 | Precipitated, naloxone (1 mg/kg, s.c.) on day 6 | Escalating morphine up to 100 mg/kg, i.p., by day 5 | Body tremor, jumping, paw tremor, ptosis, sniffing, and wet dog shakes | Rimonabant (CB ₁ inverse agonist/antagonist; 10 mg/kg) coadministered with morphine decreased jumping and wet dog shakes. SR141716A had no effect when administered alone. |
| Ramesh et al. (2013) | THC (dose NR), rimonabant (dose NR), JZL184 (4, 16, and 40 mg/kg), PF-3845 (1, 3, and 10 mg/kg), SA-57 (2.5, 5, and 12.5 mg/kg). Rimonabant, JZL184, PF-3845, and SA-57 administered intraperitoneally; THC administered subcutaneously. | Mouse | 10 to 11 | Spontaneous, morphine pellets extracted on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Body weight, diarrhea, head, shakes, and paw tremors | JZL184 (MAGL inhibitor) decreased body weight, diarrhea, and paw tremors at all doses, and head shakes and jumping at 16 and 40 mg/kg. Rimonabant reversed all effects of JZL184 (40 mg/kg). PF-3845 (FAAH inhibitor) decreased head shakes, jumping, and paw tremors (10 mg/kg). THC blocked all withdrawal signs. JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) decreased all withdrawal signs. SA-57 (dual FAAH/MAGL inhibitor) decreased diarrhea, jumping, and paw flutters (2.5 and 5 mg/kg), and head shakes (5 mg/kg). |

Rat ≥6

(continued)

TABLE 4—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Doses and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|-----------------------------|--|---------|-------------|--|---|--|---|
| Rubino et al. (2000) | Rimonobant (10 mg/kg per day). Administered intraperitoneally. | | | Precipitated, naloxone (10 mg/kg, i.p.) on day 5 (AM and PM sessions) | Morphine (75 mg) subcutaneous implant for 5 days | Digging, grooming, head shakes, jumping, penile licking, rearing, salivation, teeth chattering, wet dog shakes, writhing, and total withdrawal score | Rimonobant (CB ₁ inverse agonist/antagonist; 10 mg/kg per day) decreased diarrhea, digging, teeth chattering, penile licking, and total withdrawal score. SR141716A increased salivation. |
| Shahidi and Hasenein (2011) | URB597 (0.03, 0.1, 0.3, 0.5, and 1 mg/kg). Administered intraperitoneally. | Rat | 9 | Precipitated, naloxone (3 mg/kg, s.c.) on day 8 | Escalating morphine doses up to 66 mg/kg, s.c., by day 7 | Body weight, face grooming, jumping paw tremor, penile licking, rearing, sniffing standing, teeth chattering, and wet dog shakes | URB597 (FAAH inhibitor) decreased body weight loss, face grooming, jumping, penis licking, sniffing, and teeth chattering (all doses tested). URB597 also decreased standing and wet dog shakes (0.1, 0.3, 0.5, and 1 mg/kg), paw tremors (0.5 mg/kg), and rearing (1 mg/kg). |
| Vela et al. (1995) | THC (10 mg/kg; experiment 1 only), anandamide (0.1, 1, and 5 mg/kg). Administered intravenously. | Mice | 8–15 | Experiment 1: precipitated, naloxone (1 mg/kg, i.p.) on day 3; experiment 2: precipitated, naloxone (5 mg/kg, s.c.) on day 5 | Experiment 1: morphine (75 mg) subcutaneous implant for days; experiment 2: escalating, morphine (route NR) doses up to 45 mg/kg by day 5 | Body weight and jumping | Experiment 1: anandamide decreased jumping (5 mg/kg) and body weight loss (1 mg/kg). THC (10 mg/kg) decreased jumping and body weight. Experiment 2: anandamide decreased body weight loss (1 and 5 mg/kg); THC, not tested. |

AM404, *N*-(4-hydroxyphenyl) arachidonylethanolamide; CB₂, cannabinoid type 2 receptor; FAAH, fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; NR, not reported.

salivation in another study (Higgins et al., 1991). The 5-HT_{2A} antagonist glemanserin has also been found to selectively reduce jumping and self-directed behaviors (Pang et al., 2016); however, the 5-HT₇ receptor-specific antagonist SB269970 increased jumping, grooming, teeth chattering, and shaking (Shahidi and Hashemi-Firouzi, 2014).

Human Withdrawal. Two studies have reported on whether the 5-HT₃ antagonist ondansetron modifies opioid withdrawal severity in humans. The first was a case report that suggested ondansetron might reduce human opioid withdrawal syndrome severity (Wakim, 2012); however, the second was a placebo-controlled within-subject empirical evaluation that found no benefit of ondansetron relative to placebo following naloxone-precipitated withdrawal (Chu et al., 2017).

Cannabinoid System

Arachidonylethanolamide (anandamide) and 2-arachidonylethanolamide are two primary (but not sole) endogenous

cannabinoid ligands that bind to and activate cannabinoid type 1 (CB₁) and type 2 receptors. CB₁ receptors are often colocalized with μ -opioid receptors (for a review, see Bloomfield et al., 2019), and cannabinoid agonists, antagonists, and endocannabinoid catabolic enzyme inhibitors have all been examined for opioid withdrawal suppression.

Preclinical Withdrawal. Several studies have reported that Δ^9 -THC, the primary psychoactive cannabinoid in the cannabis plant and a partial agonist at CB₁ receptors, reduced withdrawal-related jumping and other escape behaviors, wet dog shakes, gastrointestinal symptoms, and shaking in rodents (Hine et al., 1975a,b,c; Bhargava, 1976; Lichtman et al., 2001; Cichewicz and Welch, 2003), although additional studies reported no beneficial effect of THC on jumping (Lichtman et al., 2001) or diarrhea (Lichtman et al., 2001; Cichewicz and Welch, 2003). Direct administration of the endogenous cannabinoid anandamide was found to decrease jumping and weight loss (Vela et al., 1995); however, increasing anandamide through inhibition of its catabolic

TABLE 5
 Preclinical examination of the orexin/hypocretin system on the opioid withdrawal syndrome
 Only results pertaining to effects of non-opioid drugs on opioid withdrawal symptoms are presented.

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) ^a | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|--------------------------------|---|---------|-------------|---|--|--|--|
| Ahmadi-Soleimani et al. (2014) | SB-334867 (100 μ M/0.2 μ l). Direct administration to LPGI nucleus. | Rat | 8–13 | Precipitated, naloxone (2 mg/kg, i.p.). Injection occurred following morphine escalation, specific time NR | Escalating morphine (drinking water) increasing in concentrations up to 0.4 mg/ml and maintained for 15 days | Chewing, defecation, digging, genital licking, grooming, rearing, sniffing, teeth chattering, and wet dog shakes | SB-334867 decreased chewing, genital licking, grooming, rearing, and sniffing. |
| Azizi et al. (2010) | SB-334867 (100 μ M/0.2 μ l). Direct administration to locus coeruleus. | Rat | 9 | Precipitated, naloxone (1 mg/kg, i.p.) 2 hours after morphine administration on day 10 | Morphine (10 mg/kg) delivered every 12 hours for 10 days | Chewing, diarrhea, head tremor, jumping, rearing, scratching, sniffing, teeth chattering, ptosis, and wet dog shakes | SB-334867 decreased chewing, diarrhea, head tremor, scratching, teeth chattering, and wet dog shakes. |
| Davoudi et al. (2016) | SB-334867 (3 mM/0.2 μ l). Bicuculline (15 μ M/0.2 μ l). Direct administration to locus coeruleus. | Rat | 7 | Precipitated, naloxone (3 mg/kg, s.c.) on day 8 | Escalating morphine doses up to 66 mg/kg, s.c., by day 7 | Defecation, head tremor, genital licking, rearing, scratching, sniffing, teeth chattering, wet dog shake, and writhing | SB-334867 decreased defecation, head tremor, genital licking, rearing, scratching, sniffing, wet dog shakes, and writhing. Bicuculline (GABA antagonist) had no effect by itself but when coadministered with SB-334867 reversed effects on head tremor, rearing, scratching, teeth chattering, wet dog shakes, and writhing. |
| Erami et al. (2012) | SB-334867 (1 mM/5 μ l). Administered intracerebroventricularly. | Rat | 8 | Precipitated, naloxone (2 mg/kg, s.c.) on day 10 | Morphine (10 mg/kg, s.c.) delivered every 12 hours for 10 days | Chewing, climbing, defecation, diarrhea, head tremor, jumping, rearing, scratching, sniffing, teeth chattering, and wet dog shakes | SB-334867 decreased chewing, climbing, diarrhea, jumping, rearing, rhinorrhea, and teeth chattering. |
| Ghaemi-Jandabi et al. (2014) | Orexin A (100 μ M/200 nl); SB-334867 (100 μ M/200 nl). Direct administration to locus coeruleus. | Rat | 6 to 7 | Precipitated, OXA (0.2 μ l) injection to locus coeruleus on day 10 | Morphine (10 mg/kg, s.c.) delivered every 12 hours for 9 days | Chewing, head tremor, paw tremor, rearing, scratching, sniffing, teeth chattering, and wet dog shakes | OXA increased chewing, head tremor, rearing, scratching, and wet dog shakes. SB-33847 decreased chewing, head tremor, paw tremor, scratching, sniffing, and teeth chattering. |
| Hooshmand et al. (2017) | SB-334867 (3 mM/200 nl) + glutamate (100 nM/200 nl). Direct administration to locus coeruleus. | Rat | NR | Precipitated, glutamate (100 nM/200 nl) injection to locus coeruleus on day 7 | Escalating morphine up to 66 mg/kg, s.c., by day 7 | Chewing, defecation, head tremor, paw tremor, rearing, scratching, sniffing, teeth chattering, wet dog shakes, and writhing | Glutamate increased chewing, paw tremor rearing, scratching, sniffing, wet dog shakes, and writhing. SB-334867 pretreatment did not attenuate glutamate-precipitated withdrawal during the day (rest phase) but decreased chewing, head tremor, paw tremor, rearing, sniffing, scratching, teeth chattering, wet dog shakes, and writhing during the night (active phase). |
| Hooshmandi et al. (2017) | | Rat | 12 | | | Activity, chewing, diarrhea, head tremor, freezing, | SB-334867 decreased chewing, diarrhea, freezing, penile licking, |

(continued)

TABLE 5—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) ^a | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|-----------------------|--|---------|-------------|--|--|--|---|
| | SB-334867 (0.5 µg/0.5 µl). Direct administration to dorsal hippocampus. | | | Precipitated, naloxone (1.5 mg/kg, i.p.) on day 10 | Morphine (10 mg/kg, s.c.) delivered every 12 hours for 9 days. | penile licking, ptosis, rearing, rubbing, scratching, sniffing, teeth chattering, wet dog shakes, and writhing | ptosis, scratching, teeth chattering, wet dog shakes, and writhing. |
| Laorden et al. (2012) | SB-334867 (20 mg/kg). Administered intraperitoneally. | Rat | 4–8 | Precipitated, naloxone (1 mg/kg, s.c.) on day 6 | Morphine (150 mg) subcutaneous implant for 6 days | Diarrhea, jumping, mastication, paw tremor, piloerection, ptosis, sniffing, teeth chattering, tremor, wet dog shakes, and writhing | SB-334867 decreased body tremor, diarrhea, mastication, piloerection, ptosis, sniffing, wet dog shakes, and writhing. Global withdrawal score also decreased. |
| Sharf et al. (2008) | SB-334867 (0, 20 mg/kg). Direct administration to nucleus accumbens. | Mouse | 9 | Precipitated, naloxone (1 mg/kg, s.c.) 2 hours after morphine administration | Escalating morphine doses up to 100 mg/kg, i.p., for 2.5 days | Backward walking, gnawing, head swoops, jumping, paw tremors, ptosis, tremors, and wet dog shakes | SB-334867 decreased backward walking, ptosis, tremors, wet dog shakes, and global withdrawal score (sum of withdrawal symptoms). |

LP/Gi, lateral paraventricular nucleus; NR, not reported.
^aAll drugs were administered to specific brain regions, except where noted.

enzymes using the fatty acid amide hydrolase inhibitor URB597, monoacylglycerol lipase inhibitor JZL184, or dual fatty acid amide hydrolase/monoacylglycerol lipase inhibitor SA-57 increased jumping again (Shahidi and Hasanein, 2011; Gamage et al., 2015). In addition, URB597 also decreased signs of wet dog shakes, teeth chattering, tremors, and self-directed behaviors (Shahidi and Hasanein, 2011). However, this effect may be compound specific since the fatty acid amide hydrolase inhibitor PF-3845 had no effect on jumping when administered alone (Gamage et al., 2015), although reductions in jumping, tremors, shakes, and diarrhea were observed when a high dose of PF-3845 was combined with low doses of JZL184 and SA-57 (Ramesh et al., 2013). Further complicating this issue is the fact that the anandamide-transport inhibitor *N*-(4-hydroxyphenyl) arachidonylethanolamide, which increases synaptic anandamide levels, blocked signs of spontaneous but not naloxone-precipitated withdrawal (Del Arco et al., 2002), suggesting these two syndromes may have different underlying mechanisms. The only study to examine a cannabinoid type 2 receptor-specific agonist (AM1710) on opioid withdrawal found it also reduced jumping (Li et al., 2019).

Finally, chronic exposure to the CB₁ inverse agonist/antagonist SR141716A (Rimonobant) selectively reduced jumping (Rubino et al., 2000; Mas-Nieto et al., 2001), wet dog shakes (Mas-Nieto et al., 2001), teeth chattering, self-directed behaviors, and diarrhea (Rubino et al., 2000), while not changing other measured behaviors.

Human Withdrawal. The human clinical evidence for the therapeutic effectiveness of cannabinoids during opioid withdrawal is limited and focused largely on the cannabis plant or THC. The earliest evidence of a potential therapeutic application of cannabis for opioid withdrawal is a case report from 1889, wherein a patient being withdrawn from the opioid laudanum showed immediate improvement in symptoms following cannabis administration, evidenced by being able to “take a turn around the verandah with the aid of a stick” (Birch, 1889). More recent retrospective reports have provided mixed support for cannabis treatment of opioid withdrawal. One secondary analysis of patients undergoing a methadone taper found no evidence that urine samples, which indicated recent cannabis use, were associated with better outcomes, concluding that cannabis use did not meaningfully improve withdrawal management (Epstein and Preston, 2015). A second retrospective chart review reported that 33% and 66% of patients using cannabis during opioid withdrawal found it to increase and decrease withdrawal severity, respectively (Gossop et al., 1991). Human empirical studies have generally examined whether the synthetic THC product dronabinol improves opioid withdrawal management. One randomized study in patients undergoing opioid-assisted withdrawal reported lower withdrawal ratings in participants receiving dronabinol versus placebo (Bisaga et al., 2015), and a second randomized human laboratory study in participants undergoing abrupt opioid discontinuation found that dronabinol modestly reduced withdrawal relative to placebo (Lofwall et al., 2016). However, dronabinol administration during opioid withdrawal has been observed to produce clinically significant levels of tachycardia (Jicha et al., 2015) and intoxication (Lofwall et al., 2016); suggesting its therapeutic window for this indication may be narrow.

TABLE 6
Preclinical examinations of the glutamate system on the opioid withdrawal syndrome
Only results pertaining to effects of non-opioid drugs on opioid withdrawal symptoms are presented.

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Doses and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specified Results |
|--------------------------------|---|---------|-------------|--|---|--|--|
| Fundytyus and Coderre (1994) | MK-801, GYKI 52466, (S)-4C-PG, and L-AP3 (same dose schedule: 1.6, 8, and 40 nmol). Administered intracerebroventricularly. | Rat | 4–10 | Precipitated, naloxone (1 mg/kg, s.c.), on day 7 | Morphine (36.65 μ mol/day) administered subcutaneously via pump | Jumping, teeth chattering, wet dog shakes, and writing | MK-801 (NMDA antagonist), (S)-4C-PG (metabotropic receptor antagonist), and L-AP3 (metabotropic receptor antagonist) dose dependently reduced teeth chattering and writing, as well as time spent in withdrawal. GYKI 52466 (AMPA/kainate receptor antagonist) had no effect. |
| Fundytyus and Coderre (1997) | (1S,3R)-ACPD, DHPG, and L-AP4 (same dose schedule: 0.12, 0.6, and 3 nmol), DCG-IV (4.8 or 24 pmol). Administered intracerebroventricularly. | Rat | 11–18 | Precipitated, naloxone (1 mg/kg, s.c.), on day 7 | Morphine (36.65 μ mol/day) administered subcutaneously via pump | Diarrhea, eye twitch, salivation, teeth chattering, and writing | (1S,3R)-ACPD (mGlu non-specific) decreased eye twitch severity and time spent in withdrawal. DCG-IV (mGlu _{2/3} antagonist) decreased diarrhea, eye twitch, salivation, and time spent in withdrawal. L-AP4 (mGlu ₄ antagonist) increased eye twitch. DHPG (mGlu _{1/5} antagonist) had no significant effect. |
| Fundytyus et al. (1997) | MCPG, MCCG, and MAP4 (same dose schedule: 1.6, 8, and 40 nmol/day). Administered intracerebroventricularly. | Rat | 17–20 | Precipitated, naloxone (1 mg/kg, s.c.), on day 7 | Morphine (75 mg) subcutaneous implant for 3 days | Chewing, diarrhea, lacrimation, penile grooming, ptosis, salivation, stretching, teeth chattering, vocalization on touch, wet dog shakes, and total withdrawal score | MCPG (mGlu nonselective antagonist) decreased jumps, vocalization, wet dog shakes, and time spent in withdrawal. MCCG (mGlu _{2/3} antagonist) decreased jumping, wet dog shakes, and time spent in withdrawal. MAP4 (mGlu _{4,6/7,8} antagonist) decreased time spent in withdrawal. |
| Kosten et al. (1995) | Felbamate (100 and 300 mg/kg), D-cycloserine (3 and 10 mg/kg), \pm HA-966 (3, 10 mg/kg). Administered intraperitoneally. | Rat | 6 | Precipitated, naloxone (10 mg/kg, s.c.) on day 4 | Morphine (75 mg) subcutaneous implant for 3 days | Chewing, diarrhea, lacrimation, penile grooming, ptosis, salivation, stretching, teeth chattering, vocalization on touch, wet dog shakes, and total withdrawal score | Felbamate (glycine antagonist) decreased frequency of chewing, penile grooming, teeth chattering, and severity of salivation in a linear manner across doses. D-cycloserine (glycine agonist) decreased withdrawal severity at both doses but not in a linear way. \pm HA-966 (partial glycine agonist) had no effect. |
| Kotlinska and Bochenski (2007) | MTEP (23 and 10 mg/kg), EMQMCN (5 and 20 mg/kg). Administered intraperitoneally. | Mouse | 8–10 | Precipitated, naloxone (4 mp kg, i.p.) on day 3 | Morphine sensitization procedure for 13 days (10 mg/kg, i.p., every 3 days) | Jumping | MTEP (mGlu ₅ antagonist) 10 mg decreased jumping. |

(continued)

TABLE 6—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Doses and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specified Results |
|----------------------------------|--|---------|-------------|--|---|--|---|
| Leal et al. (2003) | Ibogaine (40 and 80 mg/kg), MK-801 (0.15, and 0.3 mg/kg), Ibogaine (40 mg/kg) + MK-801 (0.15 mg/kg). Administered intraperitoneally. | Mouse | 10–13 | Precipitated, naloxone (5 mg/kg, i.p.) on day 4 | followed by morphine (37.5 mg) subcutaneous implant for 3 days Escalating morphine doses up to 225 mg/kg, i.p., by day 3 | Jumping | EMQMCM (mGlu ₁ antagonist) had no effect. All doses of ibogaine and MK-801 (NMDA antagonist) decreased jumping. Ibogaine (40 mg/kg) and MK-801 (0.15 mg/kg) coadministration decreased jumping at the level observed for the high dose of each drug independently. Ceftriaxone (glutamate transporter inhibitor) (200 mg/kg) decreased jumping, mastication, teeth chattering, and total withdrawal. Topiramate (glutamate release inhibitor) (40 mg/kg) reduced exploring, jumping, mastication, wet dog shakes (all doses), and total withdrawal score. |
| Medrano et al. (2015) | Ceftriaxone (100 and 200 mg/kg), Topiramate (20 and 40 mg/kg). Administered intraperitoneally. | Rat | 8–10 | Precipitated, naloxone (10 mg/kg, i.p.) on day 4 | Morphine (200 mg/kg) subcutaneous implant for 3 days | Abnormal posture, body weight, diarrhea, exploring, ear blanching, eye twitching, jumping, lacrimation, mastication, penile erection, ejaculation, piloerection, ptosis, rhinorrhea, teeth chattering, vocalization on touch, and wet dog shakes | |
| Patucha-Poniewiera et al. (2009) | ACPT-1 (2.5, 10, 30 mg/kg). Administered intraperitoneally. | Mouse | 8–10 | Precipitated, naloxone (4 mg/kg, i.p.) on day 4 | Morphine (30 mg/kg, i.p.) for 3 days, with an additional dose on day 4 | Body tremor, body weight, jumping, paw shake, and wet dog shakes | ACPT-1 (mGlu _{2/3} agonist) decreased body tremor (all doses), body weight (10 and 30 mg), jumping (10 mg), paw shakes (10 and 30 mg), and wet dog shakes (all doses). |
| Rasmussen et al. (1996) | LY293558 (0.1, 10, and 30 mg/kg). Administered intraperitoneally. | Rat | 10–12 | Precipitated, naloxone (10 mg/kg, s.c.) on day 4 | Morphine (150 mg) subcutaneous implant for 2 days | Body weight, chewing, diarrhea, digging, jumping, irritability, jumping, lacrimation, ptosis, salivation, stereotyped head movements, teeth chattering, tremor, wet dog shakes, writhing, and total withdrawal score | LY293558 (AMPA antagonist) dose dependently decreased total withdrawal score; specific dose-dependent decreases in chewing, diarrhea, lacrimation, ptosis, salivation, chattering, stretching head movements, wet dog shakes, and writhing. |
| Rasmussen et al. (2005) | MPEP (1, 3, and 10 mg/kg), MTEP (1, 3, and 10 mg/kg). Administered intraperitoneally. | Rat | 6–16 | Precipitated, naloxone (10 mg/kg, s.c.) on day 3 | Morphine (75 mg) subcutaneous implant for 2 days | Body weight, chewing, diarrhea, digging, erection, irritability, jumping, lacrimation, ptosis, salivation, teeth chattering, wet dog shakes, writhing, and total withdrawal score | MPEP (mGlu ₅ antagonist) reduced total withdrawal score at all doses tested and decreased body weight, chewing, digging, erection (1 mg/kg only), jumping, and teeth chattering (3 mg/kg only). MTEP (mGlu ₅ antagonist) 3 and 10 mg/kg reduced total withdrawal score and body weight, chewing, digging, |

(continued)

TABLE 6—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Doses and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specified Results |
|----------------------------------|--|---------|-------------|--|---|--|--|
| Sekiya et al. (2004) | DL-TBOA (1, 3, 10 nmol). Administered intracerebroventricularly. | Rat | 6–7 | Precipitated, naloxone (0.1 mg/kg, i.p.) on day 5 | Morphine (150 mg) subcutaneous implant for 5 days | Backward walking, body weight, ejaculation, head shaking, jumping, paw teeth chattering, wet dog shakes | erection (1 and 3 mg/kg only), and writhing. DL-TBOA (glutamate uptake inhibitor) dose dependently increased ejaculation, rhinorrhea, salivation, teeth chattering, and wet dog shakes. |
| Tanganelli et al. (1991) | MK-801 (0.1, 0.3, and 1 mg/kg), glutamic acid diethyl ester (100–500 mg/kg), pyroglutamic acid (500–1000 mg/kg). Administered intraperitoneally. | Mouse | 15–20 | Precipitated, naloxone (3 mg/kg, s.c.) on day 2 | Morphine (75 mg) subcutaneous implant for 2 days | Hyperactivity and jumping | MK-801 (NMDA antagonist) 0.3 and 1 mg/kg decreased jumping. Glutamic acid diethyl ester had no effect. Pyroglutamic acid (non-NMDA antagonist) 1000 mg/kg decreased jumping. |
| Tokuyama et al. (1996) | MK-801 (0.1 mg/kg). Administered intraperitoneally. | Rat | 10–14 | Precipitated, naloxone (48 nmol/5 μ l, LC) or glutamate (1 and 10 nmol/5 μ l, LC) 2 hours after last opioid infusion | Morphine (26 nmol/ μ l per hour) or butorphanol (26 nmol/ μ l per hour) intracerebroventricular osmotic minipump infusions for 3 days | Body weight, escape behavior, locomotion, penis licking, ptosis, rearing, salivation, scratching, teeth chattering, and wet dog shakes | Glutamate increased all withdrawal signs at both doses. MK-801 (NMDA antagonist) decreased all signs of withdrawal that were precipitated by either glutamate or naloxone. |
| Tokuyama et al. (1998) | H-7 (1 and 10 nmol/ μ l per hour) intracerebroventricular osmotic minipump infusions. | Rat | 7 | Precipitated, naloxone (24 and 48 nmol/5 μ l, i.c.v.) or glutamate (1 and 10 nmol/5 μ l, LC) 2 hours after opioid infusion | Morphine (26 nmol/ μ l per hour) or butorphanol (26 nmol/ μ l per hour) intracerebroventricular osmotic minipump infusion for 3 days | Body weight, escape behavior, locomotion, penis licking, ptosis, rearing, salivation, stretching, teeth, chattering, and wet dog shakes | Glutamate increased all signs except weight loss and salivation. H-7 (cAMP inhibitor) dose dependently decreased escape behavior, locomotion, penis licking, ptosis, rearing, salivation, stretching, and teeth chattering. Outcomes are dependent on dependence and withdrawal method used. |
| Vandergriff and Rasmussen (1999) | LY354740 (3, 10, and 30 mg/kg), LY317207 (30 mg/kg). Administered subcutaneously. | Rat | 8 | Precipitated, naltrexone (10 mg/kg, s.c.) on day 3 | Morphine (300 g) subcutaneous implant for 2 days | Body weight, chewing, diarrhea, digging, erections, irritability, jumping, lacrimation, ptosis, salivation, stereotyped head movements, teeth chattering, wet dog shakes, writhing, and total withdrawal score | LY354740 (mGlu _{2/3} agonist) dose dependently decreased total withdrawal score, chewing, diarrhea, digging, and salivation. Wet dog shakes and ptosis significantly decreased at 30 mg/kg only. LY317207 (inactive LY354740 enantiomer) had no effect. |
| Watanabe et al. (2002) | CNQX (10 and 30 nmol), MK-801 (10 and 30 nmol), D-CPPene (0.001, 0.1, and 0.1 nmol) infusion to central nucleus of the amygdala | Rat | 5–9 | Precipitated, naloxone (0.3 mg/kg, i.p.) on day 4 | Morphine (75 mg) subcutaneous implant for 2 days | Backward walking, body weight, diarrhea, head lacrimation, paw shakes, ptosis, rearing, rhinorrhea, salivation, stretching, teeth chattering, and wet dog shakes | CNQX (AMPA/kainate antagonist) decreased backward walk, body weight loss, diarrhea, head shakes, paw shakes, ptosis, rhinorrhea, teeth chattering, and wet dog shakes. MK-801 (NMDA antagonist) and D-CPPene (NMDA antagonist) had no effect. |

CNQX, 6-cyano-7-nitroquinoline-2,3-dione; LC, locus coeruleus; NR, not reported.

Orexin/Hypocretin System

The orexin (OX)/hypocretin system (hereinafter referred to as orexin) is composed of two endogenous peptides (OXA and OXB) and two receptors (OX_{1R} and OX_{2R}) (for a review, see Wang et al., 2018). Orexin is the most recently discovered of the systems reviewed herein (de Lecea et al., 1998; Sakurai et al., 1998), and there is a correspondingly limited number of pharmacological probes available to assess its role in opioid withdrawal. However, there is substantial rationale for evaluating this system. Orexin signaling generally promotes wakefulness, and the FDA has recently approved the dual OX_{1R}/OX_{2R} antagonist suvorexant (Belsomra) based on evidence that it promotes sleep and improves sleep architecture (Herring et al., 2016). Acute opioid withdrawal significantly disrupts sleep (Oyefeso et al., 1997), and pronounced protracted abnormal rapid eye movement sleep patterns are evident during both preclinical (Khazan and Colasanti, 1972; Colasanti et al., 1975) and human withdrawal (Mehtry et al., 2014). Since less sleep impairment is significantly associated with better withdrawal outcomes (Warden et al., 2012; Dunn et al., 2015), the orexin system is a logical target to address withdrawal-precipitated insomnia. Despite this evidence base, no preclinical or human studies have assessed the role of orexin in opioid-related insomnia; rather, the following studies all provide evidence that the orexin system confers benefits on other non-sleep-related withdrawal symptoms. There are no human studies examining the orexin system during withdrawal; therefore, herein only preclinical studies are reviewed.

Preclinical Withdrawal. Direct administration of OXA (which preferentially binds to OX_{1R}) increases self-directed behaviors, wet dog shakes, teeth chattering, and tremors, which can be blocked by pretreatment with the OX_{1R} antagonist SB-334867 (Ghaemi-Jandabi et al., 2014). SB-334867 also reduced chewing, diarrhea, jumping, ptosis, shaking, wet dog shakes, and other signs when administered by itself (Azizi et al., 2010; Erami et al., 2012; Ahmadi-Soleimani et al., 2014; Hooshmandi et al., 2017) or prior to naloxone-precipitated withdrawal (Laorden et al., 2012), although in the latter case it did increase teeth chattering (Laorden et al., 2012). This, combined with evidence that direct administration of SB-334867 to the nucleus accumbens reduced self-directed behaviors, wet dog shakes, tremors, ptosis, gnawing, and global withdrawal scores (Sharf et al., 2008), strongly implicates the orexin system in the expression of some withdrawal symptoms. However, when SB-334867 is administered to the locus coeruleus following GABA_A antagonist pretreatment, its beneficial effects on withdrawal are attenuated, suggesting that orexin modulation of opioid withdrawal may be due to OX_{1R} and GABA interactions in the locus coeruleus (Davoudi et al., 2016). The complexity of orexin's role in opioid withdrawal is further illustrated by a study that found OX_{1R}-dependent withdrawal reduction was limited to the active dark cycle phase, suggesting orexin-specific effects on withdrawal may be dependent on circadian rhythms and relegated to wakefulness and possibly drug seeking (Hooshmand et al., 2017).

Glutamate System

The glutamate system is comprised of ionotropic glutamate [iGlu], AMPA and NMDA] and metabotropic glutamate

[(mGlu), mGlu₁₋₅] receptors that are ubiquitously distributed throughout the brain and are being actively investigated for their role in a wide range of substance use disorders (for a review, see Niciu et al., 2012). A convergence of evidence suggests that iGlu antagonists, mGlu_{2/3} agonists, and mGlu₅ antagonists reduce the severity of some opioid withdrawal symptoms.

Preclinical Withdrawal. Glutamate appears to increase, and glutamate antagonism appears to decrease, opioid withdrawal severity. For instance, increasing glutamate levels by directly injecting glutamate into the locus coeruleus (Tokuyama et al., 1998) or through pretreatment with the glutamate transporter inhibitor DL-TBOA, increases stretching, wet dog shakes, and teeth chattering (Sekiya et al., 2004). Decreasing glutamate levels through administration of the β -lactam antibiotic ceftriaxone (which upregulates the glutamate transporter) decreased jumping and teeth chattering in rats (Medrano et al., 2015), and increasing glutamate by coadministering dihydrokainic acid to block ceftriaxone increased withdrawal symptoms again (Medrano et al., 2015). Opioid withdrawal was also completely suppressed in rats that received an infusion of the protein kinase inhibitor H-7 to reduce glutamate in the locus coeruleus (Tokuyama et al., 1996).

Additional evidence supports targeting the iGlu NMDA and AMPA receptors for opioid withdrawal. Pretreatment with the NMDA receptor antagonist dextromethorphan reduced chewing and paw shakes relative to a control condition and independent of the coadministration of the CYP2D6-inhibitor quinidine, which is generally required for humans to achieve a therapeutic effect of dextromethorphan (Bisaga et al., 2008). The NMDA antagonist MK-801 reduced jumping and the overall duration of withdrawal (Tanganelli et al., 1991; Fundytus and Coderre, 1994; Tokuyama et al., 1996; Leal et al., 2003), although it increased wet dog shakes (Fundytus and Coderre, 1994). Pretreatment with felbamate and D-cycloserine (an antagonist and agonist, respectively) at the glycine site of the NMDA receptor decreased withdrawal, although only felbamate did so in a linear, dose-dependent manner (Kosten et al., 1995). Both AMPA-receptor antagonists topiramate and LY293558 reduced jumping, wet dog shakes, gastrointestinal signs, mastication, ptosis, lacrimation, chewing, and writhing (Rasmussen et al., 1996; Medrano et al., 2015), and microinjection of an AMPA/kainite-glutamate-receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione into the central nucleus of the amygdala significantly reduced teeth chattering, diarrhea, and rhinorrhea (Watanabe et al., 2002). However, intracerebroventricular administration of the AMPA/kainite antagonist GYKI did not improve withdrawal (Fundytus and Coderre, 1994).

Medications targeting iGlu receptors generally have poor receptor specificity and potential for abuse or other negative side effect profiles that may limit their adoption in clinical settings (Herman et al., 1995). Research evaluating mGlu medications as alternatives to iGlu suggest they are also promising targets. For instance, the nonselective mGlu agonist (1S,3R)-ACPD and the selective mGlu_{2/3} agonist DCG-IV both reduced signs of diarrhea and salivation, as well as the overall duration of opioid withdrawal (Fundytus and Coderre, 1997). The mGlu_{2/3} receptor agonist LY354740 also dose dependently decreased wet dog shakes, hyperactivity, ptosis, gastrointestinal signs, writhes, salivation, and chews (Vandergriff and Rasmussen,

TABLE 7
Preclinical examinations of medications with multiple mechanisms of action on the opioid withdrawal syndrome
Only results pertaining to effects of non-opioid drugs on opioid withdrawal symptoms are presented.

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|--------------------------|---|---------------|-------------|---|---|--|--|
| Aceto and Bowman (1993) | Bupirone (0.2, 0.4, and 0.8 mg/kg) | Rhesus Monkey | ≥3 | Precipitated, naloxone (0.05 mg/kg, s.c.) 2 to 3 hours after last morphine administration | Morphine (3 mg/kg, s.c.) at minimum for ≥3 months | Ataxia, body sag, fighting, jaw sag, lying down, ptosis, retching, restlessness, rigid abdominal muscles, slowing, vocalization, and wet dog shakes | Bupirone dose dependently reduced rigid abdominal muscles, fighting, lying down, retching, restlessness, and vocalization and increased wet dog shakes. |
| Berthold et al. (1989) | Clonidine (0.01, 0.03, 0.1, and 0.3 mg/kg); prazosin (0.1, 1, and 4 mg/kg); spiroperidol (0.05 and 0.5 mg/kg); 8-OH-DPAT (0.5, 1, 2, 4, 8 mg/kg); RU 24969 fumerate (0.125, 0.25, 0.5, 1, 2, and 4 mg/kg); Idazoxan; (–)-pindolol (1, 2, and 4 mg/kg); (+)-SDZ 21-009 (1 mg/kg); (–)-SDZ 21-009 (1 mg/kg); buspirone (1, 2, 5, and 10 mg/kg); ipsapirone (1, 3, and 10 mg/kg); yohimbine (0.5 and 2 mg/kg); flesinoxan (0.5, 1, and 3 mg/kg); Rauwolscine (0.5 and 2 mg/kg); WY 26392 (0.5, 2 mg/kg); haloperidol (0.1, 0.5, and 1.0 mg/kg); pCPA (150 mg/kg). Administered subcutaneously. | Mouse | 10 | Precipitated, naloxone (1 mg/kg, i.p.) on day 5 | Morphine (75 mg) subcutaneous implant for 5 days | Jumping | 8-OH-DPAT (1 mg/kg), RU 24969 (0.25–4 mg/kg), buspirone (2 mg/kg) (5-HT ₁ agonists), ipsapirone (10 mg/kg), and flesinoxan (all doses) (5-HT ₁ agonists) decreased jumping. Idazoxan (all doses), prazosin (1 and 4 mg/kg), rauwolscine (2 mg/kg), WY 26392 (all doses), and yohimbine (all doses) (α-adrenoreceptor antagonists) also decreased jumping. Spiroperidol (5-HT ₁ antagonist) pretreatment had no effect alone but increased jumping from 8-OH-DPAT and buspirone; no effect of spiroperidol pretreatment on RU24969 and idazoxan. Haloperidol pretreatment enhanced 8-OH-DPAT-related jumping. Pretreatment (–)-pindolol and (–)-SDZ 21-009 (β-adrenoreceptor/5-HT _{1A} and 5-HT _{1B} antagonists) decreased ability of RU 24969 to suppress jumping. (+)-SDZ21-009 did not impact RU 24969. 8-OH-DPAT unaffected by (–)-pindolol, pCPA, clonidine (α ₂ agonist), and (–)-pindolol had no effects. |
| Cappendijk et al. (1994) | β-Carboline (20 mg/kg), Ibogaine (40 mg/kg). Administered intraperitoneally. | Rat | 10 | Precipitated, naloxone (4 mg/kg, i.p.) on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Chewing, diarrhea, grooming, jumping, penile licking, ptosis, rearing, rhinorrhea, teeth-chattering, wet dog shakes, vocalization on touch, and total withdrawal score | β-Carboline (20 mg/kg) decreased the total withdrawal score, chewing, diarrhea, grooming, penile licking, rearing, and teeth chattering. Ibogaine decreased the total withdrawal score, chewing, diarrhea, penile licking, and teeth chattering. |
| Dzolic et al. (1988) | Ibogaine (4, 8, and 16 μg). Administered intracerebroventricularly. | Rat | 10 | Precipitated, naloxone (5 mg/kg, i.p.) on day 3 | Morphine (85 mg) subcutaneous implant for 3 days | Chewing, diarrhea, digging, ejaculation, grooming, head holding, head shakes, jumping, paw tremor, penile licking, ptosis, rearing, | Ibogaine significantly reduced jumping and salivation (8 and 16 μg), chewing, digging, head hiding, penile licking, rearing, teeth chattering, and writhing (all doses), relative to |

(continued)

TABLE 7—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|---------------------------|---|---------|-------------|--|---|--|--|
| Francés et al. (1992) | Ibogaine (30 mg/kg). Administered intraperitoneally. | Mouse | 5–32 | Precipitated, naloxone (5 mg/kg, i.p.) on day 1, 2, 3, 4, or 5 (varied based on group) | Escalating morphine doses up to 100 mg/kg, i.p., for up to 5 days (varied based on group) | rhinorrhea, salivation, scratching, stretching, teeth chattering, urination, vocalization on touch, wet dog shakes, and writhing | cerebrospinal fluid control condition. |
| Glick et al. (1992) | Ibogaine (20, 40, and 80 mg/kg). Administered intraperitoneally. | Rat | 7–17 | Precipitated, naltrexone (1 mg/kg, i.p.) on day 6 | Morphine (50 mg) subcutaneous implant for 5 days | Body shakes, body weight, drooping, diarrhea, and jumping | Ibogaine (30 mg/kg) increased jumping and did not decrease any withdrawal signs. |
| Hine et al. (1975a) | Cannabidiol (10 mg, kg). Administered intraperitoneally | Rat | 7 | Precipitated, naloxone (4 mg/kg, i.p.) on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Burying, diarrhea, grooming, paw shaking, teeth chattering, and wet dog shakes | Ibogaine decreased diarrhea, teeth chattering, and wet dog shakes (40, 80 mg/kg), and grooming (all doses). |
| Hine et al. (1975c) | THC (2 mg/kg), cannabidiol (10 mg/kg), THC (2 mg/kg) + Cannabidiol (10 mg/kg). Administered intraperitoneally. | Rat | 8 to 9 | Precipitated, naloxone (4 mg/kg, i.p.) on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Abnormal posture, chewing, defecation, diarrhea, ear blanching, ptosis, teeth chattering, vocalization, wet dog shakes, and total withdrawal score | Cannabidiol (10 mg/kg) had no effect. |
| Kang et al. (2008) | Mirtazapine (3, 10, and 30 mg/kg). Administered intraperitoneally. | Rat | 40 | Precipitated, naloxone (1 mg/kg, i.p.) on day 10 | Morphine 10 mg, s.c., twice a day for 10 days | Abnormal posture, audible grinding, chewing, defecation, escapes, diarrhea, ear blanching, ptosis, teeth chattering, vocalization on touch, wet dog shakes, and writhing | THC (2 mg/kg) decreased total withdrawal scores and defecation, and diarrhea. Cannabidiol alone had no effect. THC (2 mg/kg) + Cannabidiol (10 mg/kg) decreased total withdrawal scores, defecation, ear blanching, escapes, and wet dog shakes. |
| Koyuncuoğlu et al. (1990) | Ketamine (0.5 and 1 mg/kg, i.v.), dextromethorphan (1 and 2 mg/kg, i.p.). | Rat | 10–16 | Precipitated, naloxone (2 mg/kg, i.p.) on day 3 | Morphine (225 mg) subcutaneous implant + F16 for 3 days | Defecation, diarrhea, flying jumping, ptosis, teeth chattering, wet dog shakes, and writhing | Mirtazapine reduced chewing (10 and 30 mg/kg), and escape attendance, grooming, and teeth chattering (all doses). Mirtazapine (10 and 30 mg/kg) reduced total withdrawal score. |
| Leal et al. (2003) | Ibogaine (40 and 80 mg/kg), MK-801 (0.15 and 0.3 mg/kg), ibogaine (40 mg/kg) + MK-801 (0.15 mg/kg). Administered intraperitoneally. | Mouse | 10–13 | Precipitated, naloxone (5 mg/kg, i.p.) on day 4 | Escalating morphine doses up to 225 mg/kg, i.p., by day 3 | Jumping | Ketamine (1 mg/kg) decreased defecation, jumping, and teeth chattering, but increased wet dog shakes. Dextromethorphan (1 mg/kg) decreased flying and teeth chattering, and (2 mg/kg) decreased all signs except writhing. |
| Lu et al. (2001) | Venlafaxine (10 and 20 mg/kg). Administered intraperitoneally. | Rat | 12 | Escalating morphine doses up to | Escalating morphine doses up to 225 mg/kg, i.p., by day 3 | Body weight, diarrhea, exploring, irritability, | All doses of ibogaine and MK-801 (NMDA antagonist) decreased jumping. Ibogaine (40 mg/kg) and MK-801 (0.15 mg/kg) coadministration decreased jumping at the level observed for the high dose of each drug independently. |

(continued)

TABLE 7—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|--------------------------|--|---------|-------------------------------------|---|--|---|--|
| Mash et al. (2016) | Norbogaine (10, 30, 56, and 100 mg/kg). Intragastric administration | Mouse | 5–11 | Precipitated, naloxone (2 mg/kg, i.p.) on day 5 | 40 mg/kg, s.c., by day 5 | jumping, lacrimation, piloerection, ptosis, teeth chattering, wet dog shakes, and writhing | jumping, piloerection, and shakes. Venlafaxine (20 mg/kg per kilogram) also decreased irritability, lacrimation, wet dog shakes, and writhing. |
| Panchal et al. (2005) | 18-MC (5, 10, and 25 μ g/1 μ l). Infused into intramedial habenula, locus coeruleus, or interpeduncular nucleus. | Rat | 5–10 | Precipitated, naltrexone (1 mg/kg, i.p.) on day 8 (immediately following intracerebral drug infusion) | Escalating morphine doses up to 75 mg/kg, s.c., for 4 days Escalating morphine doses up to 80 mg/kg, s.c., for 7 days | Body tremors, diarrhea, grooming, rearing, teeth chattering, and wet dog shakes | Norbogaine decreased body tremors (30 and 100 mg/kg), paw tremors (100 mg/kg), and jumping (30, 56, and 100 mg/kg). Intramedial habenula 18-MC decreased body weight loss (10 μ g) and burying (10 μ g). Teeth chattering decreased at 5 μ g and increased at 10 μ g. Intralocus coeruleus 18-MC dose decreased diarrhea (10 μ g), burying (all doses), teeth chattering (5 and 20 μ g), and wet dog shakes (10 μ g). Intra-interpeduncular nucleus 18-MC decreased burying (5 μ g) and rearing (10 μ g) and increased diarrhea (5 μ g) and teeth chattering (20 μ g). |
| Parker and Siegel (2001) | Ibogaine (40 mg/kg). Administered intraperitoneally. | Rat | 28 total (individual group size NR) | Precipitated, naloxone (1 mg/kg, s.c.) on day 3 | Morphine (20 mg/ml) subcutaneous implant for 2 days | Mouth movements, penile licking, rearing, teeth chattering, and wet dog shakes | Ibogaine (40 mg/kg) decreased mouth movements, penile licking, and teeth chattering. |
| Rho and Glick (1998) | 18-MC (10, 20, or 40 mg/kg). Administered intraperitoneally. | Rat | 6–8 | Precipitated, naltrexone (1 mg/kg, i.p.) on day 8 | Escalating morphine up to 140 mg/kg, s.c., for 7 days | Body weight, burying, diarrhea, flinching, grooming, teeth chattering, and wet dog shakes | 18-MC decreased body weight loss (40 mg/kg), burying (20 and 40 mg/kg), diarrhea (40 mg/kg), teeth chattering (20 and 40 mg/kg), and wet dog shakes (20 mg/kg). |
| Schreiber et al. (2003) | Mianserin (25 mg/kg), trazodone (50 mg/kg), mianserin (25 mg/kg) + trazodone (50 mg/kg). Administered subcutaneously. | Mouse | >10 | Precipitated, naloxone (1 mg/kg, s.c.) | High morphine group: escalating morphine up to 160 mg/kg, s.c., by day 8; low morphine: escalating morphine up to 40 mg/kg, s.c., by day 8 | Grooming, jumping, and rearing | Mianserin (25 mg/kg), trazodone (50 mg/kg), and mianserin (25 mg/kg) + trazodone (50 mg/kg) combination reduced jumping, rearing, and grooming in both high and low morphine groups. |
| Sharpe and Jaffe (1990) | Ibogaine (5, 10, 20, and 40 mg/kg). Administered subcutaneously. | Rat | 6 | Precipitated, naloxone (0.5 mg/kg, s.c.) on day 3 | Morphine (75 mg) subcutaneous implant for 3 days | Activity, grooming, lacrimation, mouth movement, paw shakes, penile licking, rhinorrhea, salivation, stretching, teeth chattering, wet dog shakes, and total withdrawal score | Ibogaine decreased grooming (10 mg/kg) and increased teeth chattering (5 mg/kg). |
| Streel et al. (2005) | Ketamine (2.5 mg/kg), Midazolam (0.25 mg/kg). Administered intramuscularly | Rat | 10 | Precipitated, naloxone (1 mg/kg, s.c.) on day 3, | Escalating morphine up to 150 mg/kg, s.c., for 3 days | Abnormal posture, cheek tremors, defecation, escape attempts, head | Ketamine (2.5 mg/kg) decreased defecation, urination, and total withdrawal scores. Midazolam |

(continued)

TABLE 7—Continued

| Reference | Drugs Evaluated for Opioid Withdrawal Outcomes (Dose and Route) | Species | Sample Size | Withdrawal Method | Dependence Method | Withdrawal Signs Assessed | Summary of Withdrawal-Specific Results |
|-----------|---|---------|-------------|---|-------------------|--|---|
| | | | | administered three times (total daily dose 3 mg/kg, s.c.) | | lift, jumping, mastication, salivation, sniffing, teeth chattering, urination, vocalization on touch, wet dog shakes, and total withdrawal score | (0.25 mg/kg) decreased urination and total withdrawal scores. |

pCPA, *para*-chlorophenylalanine; 18-MC, 18-methoxyrocnaridine; NR, not reported.

1999), and pretreatment with the mGlu_{2/3} receptor agonist ACPT-1 decreased jumping, wet dog shakes, and tremors (Pałucha-Poniewiera et al., 2009). The mGlu antagonists MCPG (nonselective), MCCG (mGlu_{2/3}), MAP4 (mGlu 4, 6, 7, and 8), and MPEP or MTEP (mGlu₅ antagonists) reduced several withdrawal signs including jumping, lacrimation, ptosis, and wet dog shakes, as well as time spent in withdrawal (Fundytus et al., 1997; Rasmussen et al., 2005; Kotlinska and Bochenski, 2007). Evidence of mGlu₁ receptor antagonists are mixed; while the mGlu₁ antagonist (*S*)-4C-PG reduced teeth chattering and writhing (Fundytus and Coderre, 1994), the mGlu₁ antagonist EMQMCM did not significantly modify overall opioid withdrawal scores (Kotlinska and Bochenski, 2007).

Human Withdrawal. Several studies have examined glutamatergic agents in humans. One series of three case studies reported that withdrawal improved in patients who were transitioned from clonidine to topiramate (Zullino et al., 2002). A second case report found that patients treated with topiramate required fewer concomitant medications during detoxification (suggesting they had lower severity opioid withdrawal) relative to patients treated with other medications (Zullino et al., 2004). Empirical studies support these reports. For instance, the NMDA-antagonist memantine and the partial μ -agonist buprenorphine suppressed opioid withdrawal at comparable levels in a randomized trial, although buprenorphine was significantly more effective when only subjective ratings were evaluated (Jain et al., 2011). Memantine also reduced naloxone-precipitated withdrawal severity in patients with OUD (Bisaga et al., 2001). Dextromethorphan has also been evaluated in randomized studies. The first study observed no difference in withdrawal suppression between dextromethorphan and placebo, although the authors thought a benefit of dextromethorphan might have started to emerge during the protracted period (Lin et al., 2014). The second study found that dextromethorphan + clonidine resulted in a more mild withdrawal syndrome than clonidine alone (Malek et al., 2013), and the third study found no difference between dextromethorphan + quinidine and placebo (Akerele et al., 2008).

Medications with Multiple Mechanisms of Action

Several preclinical and the majority of human studies examining medications for opioid withdrawal management have evaluated medications that act through multiple transmitter systems, which precludes determination as to what system might be mediating the observed effects on withdrawal. However, given that the majority of medications approved for use in humans act on several systems, it is important that these studies be reviewed.

Preclinical Withdrawal. Most medications reviewed herein have prominent 5-HT effects and show positive signals for opioid withdrawal management. First, buspirone, which has strong affinity for the 5-HT_{1A} receptor and moderate antagonist affinity at the D₃ and D₄ receptors, attenuated opioid withdrawal symptoms in rhesus monkeys (Aceto and Bowman, 1993) and rats (Berthold et al., 1989). Second, venlafaxine (an antidepressant that inhibits 5-HT and 5-HT noradrenergic reuptake) decreased jumping, hyperactivity, writhing, ptosis, lacrimation, and gastrointestinal symptoms in rats (Lu et al., 2001). Third, mirtazapine (a 5-HT₂ and 5HT₃

TABLE 8

Summary of human empirical studies on the opioid withdrawal syndrome

Note that only outcomes directly related to opioid withdrawal severity are discussed. Studies may have reported additional outcomes not presented here. All medications administered via oral route unless noted. Participants in all studies had OUD unless noted. Results from all participants are reported unless noted.

| Reference | System | Medication + Dose | Design | Comparator | Sample Size | Male % | Withdrawal Type | Additional Ancillary Medications Given | Primary Withdrawal-Specific Outcome | Result |
|--------------------------------|---------------------|--|---|----------------------------|---|--------|---|---|-------------------------------------|--|
| Akerele et al. (2008) | Glutamate | Dextromethorphan (30 mg/day) + quinidine (30 mg/day) | RCT; randomized, double-blind, placebo controlled | Placebo | 31 (22 dextromethorphan + quinidine, nine placebo) | 68 | Spontaneous, withdrawn from morphine (100 mg/day, s.c.) over 4 days | Acetaminophen, antacids (medication and doses NR) | MHOWS, VAS | Dextromethorphan (30 mg/day) + quinidine (30 mg/day) did not differ significantly from placebo on any withdrawal measure (MHOWS). |
| Amiri et al. (2014) | Multiple mechanisms | Amantadine (200 mg/day) + clonidine (0.4–1.2 mg/day) | RCT; randomized, double-blind, controlled | Clonidine (0.4–1.2 mg/day) | 69 [only completer sample ($n = 60$) reported: 30 amantadine + clonidine, 30 clonidine] | 100 | Spontaneous, withdrawal from illicit opioids over 3 days | Clonazepam (1 mg), acetaminophen (500 mg) | COWS | Data from 60 completers. Amantadine (200 mg/day) + clonidine (0.4–1.2 mg/day) reduced withdrawal severity significantly more than clonidine (0.4–1.2 mg/day). |
| Bisaga et al. (2001) | Glutamate | Memantine (60 mg/day) | Human laboratory study; Modified multiple baseline, between-subjects comparison | Placebo | Eight (four memantine, four placebo) | 75 | Precipitated (naloxone, 0.4 mg, i.m.) after 4–7 days of stabilization on morphine (30 mg, four times a day) | NR | CINA, OOWS, SOWS | Memantine (60 mg/day) significantly reduced CINA and OOWS ratings of withdrawal relative to placebo when administered 6 and 54 (but not 126) hours after naloxone. Memantine also significantly reduced withdrawal AUC relative to baseline. Memantine did not significantly improve SOWS ratings relative to placebo. |
| Bisaga et al. (2015) | Cannabis | Dronabinol (30 mg/day) | RCT; randomized, double-blind, placebo controlled | Placebo | 60 (40 dronabinol, 20 placebo) | 85 | Spontaneous, withdrawn from buprenorphine (8 mg/day) over 2 days transitioned to naltrexone over 4 days | Clonidine (0.8 mg/day), clonazepam (up to SOWS 3.5 mg/day), zolpidem (10 mg/day), and other medications (unspecified) | SOWS | Dronabinol (30 mg/day) significantly reduced SOWS ratings relative to placebo during abrupt withdrawal period (days 2–4). |
| Buydens-Branchey et al. (2005) | | | RCT; randomized, double-blind | Placebo | 31 (eight placebo, eight | 100 | Spontaneous, placebo and | NR | OOWS, SOWS | Buspirone (30 mg/day; 45 mg/day) dose |

(continued)

TABLE 8—Continued

| Reference | System | Medication + Dose | Design | Comparator | Sample Size | Male | Withdrawal Type | Additional Ancillary Medications Given | Primary Withdrawal-Specific Outcome | Result |
|----------------------------------|----------------------|---|--|--|---|------|--|---|-------------------------------------|--|
| | Multiple mechani sms | Bupirone (30 mg/day; 45 mg/day) | blind, placebo controlled, four group design | | methadone taper, eight bupirone 30 mg, seven bupirone 45 mg) | | bupirone group abruptly discontinued from methadone (30 mg/day); methadone group tapered off methadone (30 mg/day) over 7 days | | | independently reduced OOWS and SOWS ratings to placebo. Bupirone 45 mg/day produced the lowest AUC value overall and conferred the most withdrawal suppression. |
| Chu et al. (2017) | Serotonin | Ondansetron (8 mg, i.v.) | Human laboratory study; double-blind, within-subject, randomi zed, crossover compari son | Placebo | 33 (non-OUT persons with chronic back pain) | 61 | Precipitated (naloxone, 0.4 mg/70 kg, i.v., or 0.8 mg/70 kg, i.v., if no response to 0.4 mg/70 kg dose) | Docusate sodium (100 mg), metoclopra mide (10 mg) | OOWS, SOWS | Ondansetron (8 mg, i.v.) did not significantly reduced naloxone-precipitated withdrawal severity relative to placebo on any measure. |
| Pérez de los Cobos et al. (2001) | Multiple mechani sms | Amantadine (flexible dosing of 200–300 mg/day) | RCT; two successive randomi zed, double-blind, placebo controlled trails | Trial 1: placebo, trial 2: methadone taper | Trial 1: 40 (19 amantadine, 21 placebo); trial 2: 40 (21 amantadine, 19 placebo). Participants in both trials had OUD and cocaine-use disorder. | 81 | Spontaneous, withdrawn from methadone (maximum 50 mg/day) over 12 days | Diazepam (dose NR) | Craving VAS, OOWS, SOWS | Amantadine (200–300 mg/day) was not significantly different from placebo on any withdrawal measure in either trial. |
| Jain et al. (2011) | Glutamate | Memantine (20 mg/day) | Human laboratory study; randomi zed, double-blind, placebo controlled | Buprenorphine (2 mg, SL) | 62 [only completer sample (n = 45) reported; 25 memantine, 20 buprenorphine] | 100 | Precipitated (naloxone, 0.4 mg, i.v.) following 5-day stabilization on dextroproprhene (650 mg day) | Zolpidem (10 mg) | OOWS, SOWS | Data from 45 completers. Buprenorphine pretreatment prior to naloxone challenge significantly decreased SOWS ratings. Neither medication significantly decreased withdrawal as rated by the OOWS. Data from 50 completers. Ketamine infusion significantly reduced OOWS ratings to |
| Jovaísa et al. (2006) | Multiple mechani sms | Ketamine (0.5 mg/kg bolus following by 0.5 mg/kg per hour infusion) | RCT; randomi zed, double-blind, placebo controlled | Placebo | 58 [only completer sample (n = 50) reported; 22 | 86 | Rapid anesthetic-assisted detoxification with series of naloxone (1.6 | Clonidine (.002 mg), carbamaapine (200 mg), | OOWS | |

(continued)

TABLE 8—Continued

| Reference | System | Medication + Dose | Design | Comparator | Sample Size | Male | Withdrawal Type | Additional Ancillary Medications Given | Primary Withdrawal-Specific Outcome | Result |
|-----------------------|----------------------|---------------------------------------|--|------------------------------------|---|------|--|--|---|---|
| Lin et al. (2008) | Multiple mechani sms | Venlafaxine (300 mg/day) | RCT; randomized, double-blind, placebo controlled | Placebo | 34 (15 venlafaxine, 19 placebo) | 88 | mg, i.v., naloxone (0.8 mg/h, i.v., infusion), and then miltrexone (100 mg via orogastric tube) under isoflurane anesthesia | Chlorpromazine (dose NR); clonidine (0.075 mg), ibuprofen (400 mg), metoclopramide (1 mg/day), hydrochloride (10 mg), loperamide (2 mg) | OOWS, VAS for withdrawal, time spent sleeping, and ancillary medication utilization | Data from 20 completers reported. Participants who received venlafaxine (300 mg/day) had significantly reduced OOWS and VAS ratings and more sleep relative to placebo. Venlafaxine participants also requested fewer ancillary medications. |
| Lin et al. (2014) | Multiple mechani sms | Dextromethorphan (240 mg/day) | RCT; randomized, double-blind, placebo controlled | Placebo | 80 [only completer sample (n = 65) reported; 33 dextromethorphan, 32 placebo] | 97 | Spontaneous, withdrawn from illicit opioid use over 7 days using lorazepam (1 mg/day), fexofenadine (240 mg/day), flurazepam (30 mg/day), trazodone (100 mg/day) | Ibuprofen (400 mg/day), lorazepam (1 mg/day), metoclopramide (1 mg/day), hydrochloride (10 mg/day), loperamide (2 mg/day), promazine (doses NR); none provided on session days | OOWS, time spent sleeping, and ancillary medication utilization | Data from 65 completers (33 dextromethorphan, 32 placebo) reported. Dextromethorphan (240 mg/day) significantly reduced OOWS ratings relative to placebo on Days 3–6. No group differences observed on time spent sleeping or ancillary medication utilization. |
| Lofwall et al. (2016) | Cannabis | Dronabinol (5, 10, 20, and 40 mg/day) | Human laboratory study; randomized, double-blind, within-subject, placebo controlled | Placebo, oxycodone (30, 60 mg/day) | 18 [only completer sample (n = 12) reported] | 50 | Spontaneous, discontinued from oxycodone (120 mg/day) for each day-long session | None provided on session days | Opioid agonist/antagonist scale, OOWS, short opiate withdrawal scale | Data from 12 completers. Oxycodone decreased all withdrawal ratings. Dronabinol (20, 30 mg/day) significantly reduced withdrawal ratings on the antagonist, OOWS, and short opiate withdrawal |

(continued)

TABLE 8—Continued

| Reference | System | Medication + Dose | Design | Comparator | Sample Size | Male | Withdrawal Type | Additional Ancillary Medications Given | Primary Withdrawal-Specific Outcome | Result |
|-------------------------------------|---------------------|--|---|-----------------------------|--|------|--|---|--|--|
| Malek et al. (2013) | Glutamate | Dextromethorphan (300 mg/day) + clonidine (0.4–1.2 mg/day) | RCT; randomized, double-blind, controlled | Clonidine (0.4–1.2 mg/day) | 60 (30 dextromethorphan + clonidine, 30 clonidine) | 100 | Spontaneous, withdrawal from illicit opioid use using clonidine (0.4–1.2 mg/day), clonazepam (3 mg/day), acetaminophen (2000 mg/day) over 3 days | NR | COWS | scales relative to placebo. Dextromethorphan (300 mg/day) + clonidine significantly reduced ratings at 24, 48, and 72 hours relative to clonidine alone. |
| Pozzi et al. (2000) | Multiple mechanisms | Trazodone (600 mg/day) | RCT; randomized, single-blind design | Clonidine (0.45–0.9 mg/day) | 45 (30 trazodone, 15 clonidine) | 80 | Spontaneous, withdrawal from methadone (20 mg/day) over 3 days transitioned to maltrexone over 4 days | Ranitidine (450 mg/day), flurazepam (30 mg), methoclopramide (doses NR), ketorolac or diclofenac (doses NR) | Study-specific observer (12 items) and self-report (13 items) withdrawal rating scales | Trazodone (up to 600 mg/day) significantly reduced self-reported withdrawal relative to clonidine during the first two taper days, no group differences in observer ratings of withdrawal. |
| Rose et al. (2003) | Multiple mechanisms | Buspirone (30 mg/day) | RCT; randomized, double-blind, placebo controlled | Placebo | 20 (group sample size NR) | 100 | Spontaneous, abruptly discontinued from methadone (mean dose 95 mg/day) over 6 days | NR | OOWS, SOWS | Buspirone (30 mg/day) significantly reduced OOWS ratings on days 5–7 and 9, and SOWS ratings on day 8, relative to placebo. |
| Srisurapanont and Jaruraisin (1998) | Multiple mechanisms | Amitriptyline (up to 100 mg/day) | RCT; randomized, double-blind, parallel design | Lorazepam (up to 4 mg/day) | 27 (13 amitriptyline, 14 lorazepam) | 100 | Spontaneous, abruptly discontinued from methadone (M doses 95 mg/day) over 6 days | Analgesics, nonsteroids anti-inflammatory drugs (specific medications and doses NR) | Short opiate withdrawal scale and sleep evaluation question naire | Amitriptyline (up to 100 mg/day) did not differ significantly from lorazepam (up to 4 mg/day) on any withdrawal outcome. Amitriptyline produced lower ratings on the ease of awakening from sleep; subscale of the sleep evaluation questionnaire relative to lorazepam. |

AUC, area under the curve; CINA, clinical inventory narcotic activity; COWS, clinical opiate withdrawal scale; MHOWS, modified Himmelsbach opioid withdrawal scale; NR, not reported; OOWS, objective opioid withdrawal scale; RCT, randomized controlled trial; SL, sublingual; SOWS, subjective opiate withdrawal scale; VAS, visual analog scale.

TABLE 9
Summary of non-experimental human studies on the opioid withdrawal syndrome

Note that only outcomes directly related to opioid withdrawal severity are discussed. Studies may have reported additional outcomes not presented here.

| Reference | System | Medication | Study Type | Sample Size | Male % | Result |
|--------------------------------------|---------------------|-------------|----------------------------|-------------|--------|---|
| Alper et al. (1999) | Multiple mechanisms | Ibogaïne | Retrospective chart review | 33 | 67 | Ibogaïne (mean = 19.3 ± 6.9 mg/kg) reduced withdrawal severity within 24 hours among 75% of individuals. |
| Birch (1889) | Cannabis | Cannabis | Case report | 1 | 100 | Cannabis reduced opioid withdrawal severity. |
| Brown and Alper (2018) | Multiple mechanisms | Ibogaïne | Prospective cohort study | 30 | 83 | Ibogaïne (mean = 1540 ± 920) reduced SOWS ratings from mean = 31 to mean = 14 within 3 days. Fifty percent of individuals reported opioid abstinence at 1-month follow-up. |
| Davis et al. (2017) ^a | Multiple mechanisms | Ibogaïne | Survey (online) | 88 | 73 | Individuals stated ibogaïne reduced or eliminated withdrawal symptoms (80% of respondents), led to sustained opioid abstinence (30%), and produced sustained reductions in opioid craving (25%). |
| Epstein and Preston (2015) | Cannabis | Cannabis | Secondary outcome from RCT | 116 | 53 | Participants completing a methadone-assisted taper (10-weeks) who did (<i>n</i> = 46) or did not (<i>n</i> = 70) provide a urine sample testing positive for cannabis during the treatment did not vary in their ratings of opioid withdrawal severity during the parent trial. |
| Gossop et al. (1991) | Cannabis | Cannabis | Retrospective chart review | 50 | 70 | Cannabis increased (24% of respondents) or decreased (12% of respondents) withdrawal severity. |
| Lalanne et al. (2016) ^b | Multiple mechanisms | Ketamine | Case report | 1 | 0 | Patient reported ketamine (1 mg/kg) successfully assisted taper off opioid medications. |
| Malcolm et al. (2018) | Multiple mechanisms | Ibogaïne | Retrospective chart review | 50 | 61 | Ibogaïne (dose NR) eliminated ratings on COWS (78% of individuals), SOWS (68%), and opioid craving (79%) 2 days after abrupt opioid discontinuation. |
| Pinkofsky et al. (2005) | Multiple mechanisms | Quetiapine | Survey (quality assurance) | 107 | 45 | Quetiapine reduced cravings (74% of individuals) anxiety (49%), somatic pain (22%), and insomnia (21%), and improved appetite (13%). Only 4% felt quetiapine had no effect. |
| Quinlan (2012) ^a | Multiple mechanisms | Ketamine | Case report | 11 | NR | Patients who received ketamine-assisted opioid detoxification reported ketamine was well-tolerated. Patients reported feeling better after 2 months (73% of respondents) and remained abstinent from opioids at 6 months (27%). |
| Sheppard (1994) | Multiple mechanisms | Ibogaïne | Case report | 7 | 71 | Ibogaïne (700–1800 mg) reduced opioid withdrawal severity at 24–38 hours. |
| Strickler et al. (2018) ^b | Multiple mechanisms | Ketamine | Case report | 1 | 100 | Ketamine (10 mg/h infusion) + clonidine patch used to successfully taper patient off opioids over 7-day period. |
| Wakim (2012) ^b | Serotonin | Ondansetron | Case report | 1 | 0 | Ondansetron (16 mg/day) used to successfully taper patients off opioids over 10-day period. |
| Zullino et al. (2002) | Glutamate | Topiramate | Case report | 3 | 67 | Topiramate (up to 500 mg/day) used to successfully taper patients off opioids over 9–14 day period. |

COWS, clinical opiate withdrawal scale; NR, not reported; RCT, randomized controlled trial; SOWS, subjective opiate withdrawal scale.

^aPatient population had chronic opioid use (population unspecified).

^bPatient population comprised of persons with acute or chronic pain and opioid use disorder.

receptor family antagonist that also blocks adrenergic autoreceptors) reduced wet dog shakes, rearing, and grooming in rats (Kang et al., 2008). Fourth, the tetracyclic mianserin, which antagonizes 5-HT and adrenergic receptors, and trazodone (a 5-HT antagonist and reuptake inhibitor) both reduced jumping, hyperactivity, and grooming in mice, although combining the two medications together did not increase either drug's effect (Schreiber et al., 2003). However, the cannabinoid cannabidiol (an inverse agonist at the CB₁ and cannabinoid type 2 receptors), which also acts as a 5HT_{1A} agonist (an allosteric modulator of μ - and δ -opioid receptors) and a positive modulator of the transient receptor vanilloid-1 (Kathmann et al., 2006), did not reduce withdrawal when administered alone but did reduce wet dog shakes and gastrointestinal distress when coadministered with THC (Hine et al., 1975a,c). Finally, neither spiperidol nor haloperidol, two antipsychotic medications with dual action as 5-HT (subtype unknown) and D₂ receptor antagonists, had an effect on withdrawal-related jumping (Berthold et al., 1989).

Several additional preclinical studies have examined whether medications with primary NMDA receptor activity reduce withdrawal severity. The most frequently researched compound is ibogaine, an NMDA antagonist that binds to κ -opioid and σ 2 receptors and inhibits nicotine receptors as well as 5-HT and DA transport (Mach et al., 1995; Alper, 2001; Bulling et al., 2012). Numerous studies have suggested that ibogaine, its primary metabolite noribogaine, and a related congener 18-methoxyroconaridine, decrease some opioid withdrawal symptoms in preclinical models (Dzolic et al., 1988; Sharpe and Jaffe, 1990; Glick et al., 1992; Cappendijk et al., 1994; Rho and Glick, 1998; Parker and Siegel, 2001; Leal et al., 2003; Panchal et al., 2005; Mash et al., 2016), although at least one study found that ibogaine increased withdrawal severity in mice (Francés et al., 1992). Ketamine, an NMDA receptor antagonist with cholinergic and opioid activity, has also been observed to reduce withdrawal (Streel et al., 2005), although it may not be more effective than dextromethorphan (Koyuncuoglu et al., 1990).

Human Withdrawal. The vast majority of human studies reviewed herein examined medications that act on the DA, 5-HT, and glutamate systems. A retrospective chart review reported the antipsychotic medication quetiapine, which antagonizes D₂ and 5-HT₂ receptors, benefited 96.3% of the patients undergoing opioid withdrawal, specifically improving opioid craving (73.8%), somatic pain (22.5%), and insomnia (20.5%) (Pinkofsky et al., 2005). Buspirone has also been shown to improve opioid withdrawal symptoms in both an open-label trial of men undergoing withdrawal from methadone (Rose et al., 2003) and in a randomized, controlled comparison of buspirone to placebo in men undergoing withdrawal from methadone (Buydens-Branchey et al., 2005). Amantadine, an NMDA antagonist that increases DA release and inhibits DA reuptake, has been shown in a randomized comparison to suppress more symptoms of withdrawal when coadministered with clonidine, relative to clonidine alone (Amiri et al., 2014). In contrast, a second study that examined amantadine for cocaine use in methadone-maintained patients observed no difference in opioid withdrawal outcomes, although the outcomes may have been impacted by ongoing cocaine (a DA reuptake inhibitor) use in that study (Pérez de los Cobos et al., 2001). An additional study that compared the tricyclic antidepressant amitriptyline

(which inhibits norepinephrine and 5-HT reuptake) to the benzodiazepine lorazepam for insomnia management during opioid withdrawal reported no differences between the two medications, although the lack of placebo condition in this study makes it difficult to determine whether either medication improved insomnia (Srisurapanont and Jarusuraisin, 1998). A randomized comparison of trazodone + naltrexone to clonidine + naltrexone for rapid withdrawal from methadone reported trazodone was as effective as clonidine in reducing overall withdrawal symptom severity and outperformed clonidine with regard to insomnia, thirst, and shivers (Pozzi et al., 2000). Finally, a randomized evaluation reported significantly lower withdrawal symptoms among participants who received venlafaxine versus placebo (Lin et al., 2008).

Several studies support targeting the glutamate system for human withdrawal management. For instance, retrospective chart reviews, surveys, and case reports all provide associative evidence that ibogaine reduces the severity of opioid withdrawal in humans (Sheppard, 1994; Alper et al., 1999; Davis et al., 2017; Brown and Alper, 2018; Malcolm et al., 2018), although no empirical studies have been published to formally support these reports. However, the widespread clinical adoption of ibogaine for OUD seems unlikely (Hoelen et al., 2009; Paling et al., 2012; Asua, 2013; Jalal et al., 2013) because it has a very narrow therapeutic window and is dangerous for persons with preexisting cardiovascular problems (Alper et al., 2012) or who plan to combine it with opioids (Mazoyer et al., 2013). Ibogaine also produced significant head and body tremors in many of the studies reviewed herein. Efforts to develop the potentially safer metabolite noribogaine for opioid withdrawal are in the beginning stages and show initial promise (Glue et al., 2015a,b; Mash et al., 2016). Another alternative to ibogaine may be ketamine, which has been supported for opioid withdrawal management in case reports of patients with chronic pain (Quinlan, 2012; Strickler et al., 2018), and a patient with OUD (Lalanne et al., 2016), as well as a randomized study that found it lowered opioid withdrawal significantly more than placebo among patients undergoing rapid naltrexone-assisted detoxification under anesthesia (Jovaiša et al., 2006). The recent FDA approval of the ketamine derivative esketamine for severe depression provides a new potential pathway through which this drug class can be examined for human opioid withdrawal management.

Discussion

The OUD trajectory generally transitions from using opioids for euphoric or pain-relieving qualities to using opioids to avoid withdrawal or craving, and avoidance of withdrawal is believed to motivate continued opioid use despite the potential to incur negative health, financial, judicial, social, and personal consequences. Therefore, opioid withdrawal symptom management is a primary goal of most OUD treatments. This review summarized preclinical and clinical evidence supporting the involvement of the DA, 5-HT, cannabinoid, orexin, and glutamate systems in the opioid withdrawal syndrome. All of the reviewed systems appeared to contribute to some but not all symptoms of withdrawal, suggesting they likely modulate but do not independently drive the opioid withdrawal syndrome. The data reviewed

herein suggest it is unlikely that medications acting on these systems will be better at suppressing withdrawal than an opioid agonist. Rather, these data suggest that medications targeting these systems should be evaluated to determine whether their coadministration with opioid agonists can improve opioid withdrawal management. Empirically evaluating medications that work on these systems can help transition the OUD treatment field from using symptomatic concomitant medications (e.g., nonsteroidal anti-inflammatory

drugs) to those supported by a mechanistic understanding of opioid withdrawal.

The fact that methadone, buprenorphine, and naltrexone are FDA approved for OUD treatment does not detract from the value of investigating additional pharmacotherapies for opioid withdrawal management—new medications to reduce opioid withdrawal are still needed. Supervised opioid withdrawal is the most frequently used form of OUD treatment (Jones et al., 2015); however, many patients leave treatment

TABLE 10
Summary of outcomes from preclinical and human empirical studies and prospective targets for evaluation

| Neurotransmitter System | Prospective Medication Targets for Evaluation | | |
|-------------------------|---|---|--|
| | Improved ≥1 Withdrawal Symptom ^a | Did Not Improve Any Withdrawal Symptoms | Approved for Use in Humans and Acts on Transmitter Systems of Interest ^b |
| Dopamine | Buspirone d-Amphetamine Desipramine Domperidone Flupenthixol Haloperidol L-DOPA Mianserin Pimozide Quetiapine | Sulpride | Acetophenazine Aripiprazole ^c Asenapine Clozapine ^c Domperidone Droperidol Fluphenazine Fluspirilene Iloperidone Loxapine Lurasidone ^c Mesoridazine Methotrimeprazine Metoclopramide Molindone Olanzapine ^c Paliperidone Perphenazine Pimozide Pipotiazine Prochlorperazine Risperidone Sulpride Ziprasidone ^c Aripiprazole ^c Brexiprazole Chlorpromazine Clozapine ^c Cyclobenzaprine Cyproheptadine Desipramine Lisuride Lorcaserin Lurasidone ^c Mirtazapine Olanzapine ^c Palonosetron Promethazine Risperidone Vortioxetine Ziprasidone ^c Cannabidiol Nabilone Suvorexant Acamprosate Phenobarbital Esketamine Guaifenesin Pentobarbital Perampanel Rufinamide Secobarbital |
| Serotonin | Buspirone Cyproheptadine Fenfluramine Glemanserin Mianserin Mirtazapine Lorcaserin Ondansetron Quetiapine Trazodone Venlafaxine | Amitriptyline | |
| Cannabinoid | Dronabinol | Cannabidiol | |
| Orexin | NR | NR | |
| Glutamate | Amantadine D-Cycloserine Felbamate Ketamine Memantine Noribogaine Topiramate | NR | |

NR, none reported.

^aMedications may be listed more than once if they act on multiple systems.

^bThe medications included here are approved for use in humans and could be evaluated for possible opioid withdrawal symptom management. Note that each medication should be assessed for its potential side effect profile and contraindications, and that some medications may have abuse liability or other features that might limit their adoption in clinical settings.

^cMedication acts on more than one target that may alleviate withdrawal.

prematurely because their withdrawal is not adequately managed and those who complete it experience protracted withdrawal and ongoing cravings (Northrup et al., 2015). This leaves patients at significant risk for relapse and fatal overdose (Degenhardt et al., 2011). Further complicating this issue is the fact that no standardized guidelines for opioid withdrawal exist. Opioid-assisted detoxifications generally coadminister opioids with other concomitant medications to manage emergent withdrawal symptoms, and detoxifications that do not use opioids rely solely on these concomitant medications. Evidence suggests that patients vary considerably in their manifestation of withdrawal (Northrup et al., 2015; Dunn et al., 2018b) and may, therefore, benefit from having a range of mechanistically informed concomitant treatments available. Improved withdrawal management is also critical for improving patient access to extended-release naltrexone, a relapse prevention treatment that blocks exogenous opioid administration and is as effective a treatment as buprenorphine once patients are able to successfully taper off their opioid medications (Tanum et al., 2017; Lee et al., 2018). By increasing patient eligibility for naltrexone, efforts to mechanistically identify concomitant medications during withdrawal could help expand OUD treatment access.

Empirically supported concomitant medications could also be used to help patients who are receiving opioids for chronic pain management, either by augmenting their treatments and potentially reducing their opioid reliance, or by assisting them in transitioning off of long-term opioid therapy in favor of other pain management strategies. For instance, several epidemiologic studies have suggested that medicinal cannabis may produce an opioid-sparing effect (Bachhuber et al., 2014; Bradford and Bradford, 2016; Campbell et al., 2018). This is of major interest in the context of the current opioid crisis, since evidence that chronic opioid exposure may not be an appropriate treatment of pain (Busse et al., 2013) has led to new guidelines recommending patients be transitioned off long-term opioid treatments (Dowell et al., 2016). Notably, interest in the potential opioid-sparing effects of cannabis has prompted several states to legislatively define OUD as an approved indication for medicinal cannabis, despite a lack of empirical support for this approach (Humphreys and Saitz, 2019) and data suggesting cannabis exposure increases the risk of developing OUD (Olson et al., 2018). Since there are also no standardized guidelines for tapering patients off of their clinically indicated pain medications, a mechanistic understanding of opioid withdrawal symptoms can help support the development of effective pain medication tapering protocols or studies on the opioid-sparing effects of cannabis and other targeted medications.

As shown in Table 10, all of the neurotransmitter systems evaluated here have corresponding medications that are FDA approved for other indications or are being actively investigated in humans, suggesting they could be repurposed for the indication of opioid withdrawal management. Advancing a medication from discovery to market can cost a billion dollars and take more than a decade (Vocci and Ling, 2005; Adams and Brantner, 2006), which is too slow a process to meaningfully impact the current opioid crisis. Examining approved medications for opioid withdrawal will also allow existing data to be leveraged to inform safety, doses, and

participant eligibility. Although repurposing a medication may expedite treatment access, the need to examine medications in a randomized design still slows the development process. To circumvent this issue, the use of a human laboratory session to model clinical withdrawal experience could be investigated as a medication development pathway. For instance, a recent study in a human OUD clinical population showed that response to a precipitated naloxone challenge was significantly associated with withdrawal response in a subsequent double-blind randomized and controlled pharmacotherapy examination (Dunn et al., 2018b). A human laboratory model was also used in some of the empirical human studies reviewed herein (Bisaga et al., 2001; Jain et al., 2011; Chu et al., 2017) and has been regularly used to screen medications for alcohol and tobacco use disorders (Perkins et al., 2008, 2013; McKee, 2009; McKee et al., 2012). Together, this evidence suggests that a laboratory model could be a promising method for screening candidate opioid withdrawal medications prior to clinical trial investigations.

This review is complicated by the fact that many of the drugs evaluated preclinically are not yet approved for human consumption; although preclinical and human symptoms cluster into similar categories (as shown in Table 1), they may not directly generalize across species. The studies were also extremely heterogeneous in nature, and despite efforts to systematically review all available literature the diverse manner in which these studies were published and indexed may have resulted in some publications being accidentally omitted. Thus, this paper should be conceptualized as a narrative summary to stimulate future investigations. Finally, despite evidence that many opioid effects may be mediated by gonadal hormones (Huhn et al., 2018) the majority of preclinical and human studies reviewed herein evaluated predominately (and often exclusively) male samples. More research is needed to determine whether medications are equally effective for both sexes, particularly in light of data suggesting hormones impact craving and relapse vulnerability for other drugs of abuse (e.g., Carpenter et al., 2006; Franklin et al., 2008).

In summary, given the scale and impact of the opioid crisis and the vast number of people throughout the world who are prescribed opioids chronically for pain management, there is a pressing need to identify mechanistically informed medications that reduce the severity of opioid withdrawal symptoms. This review provides evidence that several non-opioid systems (DA, 5-HT, cannabinoid, orexin, and glutamate) contribute to opioid withdrawal symptom severity and identifies several potential FDA-approved medications (Table 10) that could be evaluated as concomitant medications for opioid withdrawal management. The repurposing of an existing medication is a less-expensive method for drug development than a discovery-to-market approach, and the familiarity and availability of existing medications may help them to be more readily adopted in clinical settings. Developing a solid mechanistically informed treatment regimen for persons with opioid physical dependence is essential to the advancement of patient care and to improving treatment outcomes for persons experiencing opioid withdrawal.

Authorship Contributions

Wrote or contributed to the writing of the manuscript: Dunn, Huhn, Bergeria, Gipson, Weerts.

References

- Aceto MD and Bowman ER (1993) Suppression of opiate withdrawal and cocaine hyperarousal syndromes by buspirone. Possible pharmacotherapeutic applications. *Arzneimittelforschung* **43**:942–945.
- Adams CP and Brantner VV (2006) Estimating the cost of new drug development: is it really 802 million dollars? *Health Aff (Millwood)* **25**:420–428.
- Ahmadi-Soleimani SM, Ghaemi-Jandabi M, Azizi H, and Semnani S (2014) Orexin type 1 receptor antagonism in lateral paraventricular nucleus attenuates naloxone-precipitated morphine withdrawal symptoms in rats. *Neurosci Lett* **558**:62–66.
- Akerle E, Bisaga A, Sullivan MA, Garawi F, Comer SD, Thomas AA, Nunes EV, and Kleber HD (2008) Dextromethorphan and quinidine combination for heroin detoxification. *Am J Addict* **17**:176–180.
- Alper KR (2001) Ibogaine: a review. *Alkaloids Chem Biol* **56**:1–38.
- Alper KR, Lotsof HS, Frenken GM, Luciano DJ, and Bastiaans J (1999) Treatment of acute opioid withdrawal with ibogaine. *Am J Addict* **8**:234–242.
- Alper KR, Stajic M, and Gill JR (2012) Fatalities temporally associated with the ingestion of ibogaine. *J Forensic Sci* **57**:398–412.
- Amiri S, Malek A, Tofighnia F, Habibi Asl B, and Seidy A (2014) Amantadine as augmentation in managing opioid withdrawal with clonidine: a randomized controlled trial. *Iran J Psychiatry* **9**:142–146.
- Ary M and Lomax P (1976) Dopaminergic sites involved in morphine withdrawal hypothermia. *Proc West Pharmacol Soc* **19**:290–294.
- Asua I (2013) Growing menace of ibogaine toxicity. *Br J Anaesth* **111**:1029–1030.
- Azizi H, Mirnajafi-Zadeh J, Rohampour K, and Semnani S (2010) Antagonism of orexin type 1 receptors in the locus coeruleus attenuates signs of naloxone-precipitated morphine withdrawal in rats. *Neurosci Lett* **482**:255–259.
- Bachhuber MA, Saloner B, Cunningham CO, and Barry CL (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. *JAMA Intern Med* **174**:1668–1673.
- Bednarczyk B and Vetulani J (1978) Antagonism of clonidine to shaking behavior in morphine abstinence syndrome and to head twitches produced by serotonergic agents in the rat. *Pol J Pharmacol Pharm* **30**:307–322.
- Berger M, Gray JA, and Roth BL (2009) The expanded biology of serotonin. *Annu Rev Med* **60**:355–366.
- Berthold H, Fozard JR, and Engel G (1989) 5-HT₁ receptor agonists attenuate the naloxone-induced jumping behaviour in morphine-dependent mice. *Eur J Pharmacol* **162**:19–27.
- Bhargava HN (1976) Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-Δ⁹-tetrahydrocannabinol. *Eur J Pharmacol* **36**:259–262.
- Birch E (1889) The use of Indian hemp in the treatment of chronic chloral and chronic opium poisoning. *Lancet* **133**:625.
- Bisaga A, Comer SD, Ward AS, Popik P, Kleber HD, and Fischman MW (2001) The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. *Psychopharmacology (Berl)* **157**:1–10.
- Bisaga A, Kos T, Wójcikowski J, Daniel WA, and Popik P (2008) Brain levels of dextromethorphan and the intensity of opioid withdrawal in mice. *Drug Alcohol Depend* **95**:147–151.
- Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, et al. (2015) The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. *Drug Alcohol Depend* **154**:38–45.
- Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, Costello H, Ogumbiyi MO, Bossong MG, and Freeman TP (2019) The neuropsychopharmacology of cannabis: a review of human imaging studies. *Pharmacol Ther* **195**:132–161.
- Bradford AC and Bradford WD (2016) Medical marijuana laws reduce prescription medication use in medicare part D. *Health Aff (Millwood)* **35**:1230–1236.
- Brown TK and Alper K (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. *Am J Drug Alcohol Abuse* **44**:24–36.
- Bulling S, Schicker K, Zhang YW, Steinkellner T, Stockner T, Gruber CW, Boehm S, Freissmuth M, Rudnick G, Sitte HH, et al. (2012) The mechanistic basis for non-competitive ibogaine inhibition of serotonin and dopamine transporters. *J Biol Chem* **287**:18524–18534.
- Busse JW, Schandelmaier S, Kamaleldin M, Hsu S, Riva JJ, Vandvik PO, Tsoi L, Lam T, Ebrahim S, Johnston B, et al. (2013) Opioids for chronic non-cancer pain: a protocol for a systematic review of randomized controlled trials. *Syst Rev* **2**:66.
- Buydens-Branchey L, Branchey M, and Reel-Brander C (2005) Efficacy of buspirone in the treatment of opioid withdrawal. *J Clin Psychopharmacol* **25**:230–236.
- Campbell G, Hall W, and Nielsen S (2018) What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review. *Int Rev Psychiatry* **30**:91–106.
- Cappendijk SL, Fekkes D, and Dzolic MR (1994) The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine. *Behav Brain Res* **65**:117–119.
- Carpenter MJ, Upadhyaya HP, LaRowe SD, Saladin ME, and Brady KT (2006) Menstrual cycle phase effects on nicotine withdrawal and cigarette craving: a review. *Nicotine Tob Res* **8**:627–638.
- Cervo L, Rochat C, Romandini S, and Samanin R (1981) Evidence of a preferential role of brain serotonin in the mechanisms leading to naloxone-precipitated compulsive jumping in morphine-dependent rats. *Psychopharmacology (Berl)* **74**:271–274.
- Chu LF, Sun J, Clemenson A, Erlendson MJ, Rico T, Cornell E, Obasi H, Sayyid ZN, Encisco EM, Yu J, et al. (2017) Ondansetron does not reduce withdrawal in patients with physical dependence on chronic opioid therapy. *J Addict Med* **11**:342–349.
- Cichewicz DL and Welch SP (2003) Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Δ⁹-tetrahydrocannabinol. *J Pharmacol Exp Ther* **305**:812–817.
- Colasanti B, Kirchman A, and Khazan N (1975) Changes in the electroencephalogram and REM sleep time during morphine abstinence in pellet-implanted rats. *Res Commun Chem Pathol Pharmacol* **12**:163–172.
- Cox B, Ary M, and Lomax P (1976) Dopaminergic involvement in withdrawal hypothermia and thermoregulatory behavior in morphine dependent rats. *Pharmacol Biochem Behav* **4**:259–262.
- Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, and Polanco M (2017) Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. *J Psychedelic Stud* **1**:65–73.
- Davoudi M, Azizi H, Mirnajafi-Zadeh J, and Semnani S (2016) The blockade of GABA_A receptors attenuates the inhibitory effect of orexin type 1 receptors antagonist on morphine withdrawal syndrome in rats. *Neurosci Lett* **617**:201–206.
- Degenhardt L, Bucello C, Mathers B, Briegleb C, Ali H, Hickman M, and McLaren J (2011) Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. *Addiction* **106**:32–51.
- Del Arco I, Navarro M, Bilbao A, Ferrer B, Piomelli D, and Rodríguez De Fonseca F (2002) Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404. *Eur J Pharmacol* **454**:103–104.
- de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS II, et al. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci USA* **95**:322–327.
- Dole VP and Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. *JAMA* **193**:646–650.
- Dowell D, Haegerich TM, and Chou R (2016) CDC guideline for prescribing opioids for chronic pain—United States, 2016. *JAMA* **315**:1624–1645.
- Drust EG, Sloviter RS, and Connor JD (1979) Effect of morphine on 'wet-dog' shakes caused by cerebrotentorial injection of serotonin. *Pharmacology* **18**:299–305.
- Dunn KE, Finan PH, Andrew Tompkins D, and Strain EC (2018a) Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. *Addict Behav* **76**:8–14.
- Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, and Sigmon SC (2015) Characterizing opioid withdrawal during double-blind buprenorphine detoxification. *Drug Alcohol Depend* **151**:47–55.
- Dunn KE, Sigmon SC, Strain EC, Heil SH, and Higgins ST (2011) The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review. *Drug Alcohol Depend* **119**:1–9.
- Dunn KE, Weerts EM, Huhn AS, Schroeder JR, Tompkins DA, Bigelow GE, and Strain EC (2018b) Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes. *Addict Biol* DOI: 10.1111/adb.12680 [published ahead of print].
- Dzolic ED, Kaplan CD, and Dzolic MR (1988) Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats. *Arch Int Pharmacodyn Ther* **294**:64–70.
- el-Kadi AO and Sharif SI (1995) The role of 5-HT in the expression of morphine withdrawal in mice. *Life Sci* **57**:511–516.
- el-Kadi AO and Sharif SI (1998) The role of dopamine in the expression of morphine withdrawal. *Gen Pharmacol* **30**:499–505.
- Epstein DH and Preston KL (2015) No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper. *Am J Addict* **24**:323–328.
- Erami E, Azhdari-Zarmehri H, Rahmani A, Ghasemi-Dashkhasan E, Semnani S, and Haghighast A (2012) Blockade of orexin receptor 1 attenuates the development of morphine tolerance and physical dependence in rats. *Pharmacol Biochem Behav* **103**:212–219.
- Farrell M (1994) Opiate withdrawal. *Addiction* **89**:1471–1475.
- Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpää M, Hansson P, Jensen TS, et al. (2015) Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol* **14**:162–173.
- Francés B, Gout R, Cros J, and Zajac JM (1992) Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. *Fundam Clin Pharmacol* **6**:327–332.
- Franklin TR, Ehrman R, Lynch KG, Harper D, Sciortino N, O'Brien CP, and Childress AR (2008) Menstrual cycle phase at quit date predicts smoking status in an NRT treatment trial: a retrospective analysis. *J Womens Health (Larchmt)* **17**:287–292.
- Fundytus ME and Coderre TJ (1994) Effect of activity at metabotropic, as well as ionotropic (NMDA), glutamate receptors on morphine dependence. *Br J Pharmacol* **113**:1215–1220.
- Fundytus ME and Coderre TJ (1997) Attenuation of precipitated morphine withdrawal symptoms by acute i.c.v. administration of a group II mGluR agonist. *Br J Pharmacol* **121**:511–514.
- Fundytus ME, Ritchie J, and Coderre TJ (1997) Attenuation of morphine withdrawal symptoms by subtype-selective metabotropic glutamate receptor antagonists. *Br J Pharmacol* **120**:1015–1020.
- Gamage TF, Ignatowska-Jankowska BM, Muldoon PP, Cravatt BF, Damaj MI, and Lichtman AH (2015) Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice. *Drug Alcohol Depend* **146**:7–16.
- Ghaemi-Jandabi M, Azizi H, and Semnani S (2014) Blockade of orexin type 1 receptors inhibits the development of morphine tolerance in lateral paraventricular nucleus: an electrophysiological approach. *Brain Res* **1578**:14–22.
- Gianutsos G, Hynes MD, and Lal H (1976) Enhancement of morphine-withdrawal and apomorphine-induced aggression by clonidine. *Psychopharmacol Commun* **2**:165–171.
- Glick SD, Rossman K, Rao NC, Maisonneuve IM, and Carlson JN (1992) Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. *Neuropharmacology* **31**:497–500.

- Glue P, Lockhart M, Lam F, Hung N, Hung CT, and Friedhoff L (2015a) Ascending-dose study of norbogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. *J Clin Pharmacol* **55**:189–194.
- Glue P, Lockhart M, Lam F, Hung N, Hung CT, Tunnicliffe D, Cape G, Devane J, Weis H, Howes J, et al. (2015b) Evaluation of norbogaine safety, pharmacokinetics, and opioid withdrawal effects in methadone-dependent patients.
- Gold MS, Redmond DE Jr, and Kleber HD (1978) Clonidine blocks acute opiate-withdrawal symptoms. *Lancet* **2**:599–602.
- Gold MS, Redmond DE Jr, and Kleber HD (1979) Noradrenergic hyperactivity in opiate withdrawal supported by clonidine reversal of opiate withdrawal. *Am J Psychiatry* **136**:100–102.
- Gorodetzky CW, Walsh SL, Martin PR, Saxon AJ, Gullo KL, and Biswas K (2017) A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. *Drug Alcohol Depend* **176**:79–88.
- Gossop M, Battersby M, and Strang J (1991) Self-detoxification by opiate addicts. A preliminary investigation. *Br J Psychiatry* **159**:208–212.
- Gowing L, Farrell M, Ali R, and White JM (2016) Alpha₂ adrenergic agonists for the management of opioid withdrawal. *Cochrane Database Syst Rev*:CD002024 DOI: 10.1002/14651858.CD002024.
- Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, and Kanof PD (1987) Two new rating scales for opiate withdrawal. *Am J Drug Alcohol Abuse* **13**: 293–308.
- Herman BH, Vocci F, and Bridge P (1995) The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction. *Neuropsychopharmacology* **13**: 269–293.
- Herring WJ, Connor KM, Snyder E, Snively DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, et al. (2016) Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. *J Clin Sleep Med* **12**:1215–1225.
- Herz A, Bläsing J, and Papeschi R (1974) Role of catecholaminergic mechanisms in the expression of the morphine abstinence syndrome in rats. *Psychopharmacology (Berl)* **39**:121–143.
- Higgins GA, Nguyen P, Joharchi N, and Sellers EM (1991) Effects of 5-HT₃ receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal. *Psychopharmacology (Berl)* **105**:322–328.
- Hillhouse M, Domier CP, Chim D, and Ling W (2010) Provision of ancillary medications during buprenorphine detoxification does not improve treatment outcomes. *J Addict Dis* **29**:23–29.
- Hine B, Friedman E, Torrelío M, and Gershon S (1975a) Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. *Science* **187**: 443–445.
- Hine B, Torrelío M, and Gershon S (1975b) Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC. *Psychopharmacol Commun* **1**:275–283.
- Hine B, Torrelío M, and Gershon S (1975c) Differential effect of cannabidiol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. *Res Commun Chem Pathol Pharmacol* **12**:185–188.
- Hoelen DW, Spiering W, and Valk GD (2009) Long-QT syndrome induced by the antiaddictive drug ibogaine. *N Engl J Med* **360**:308–309.
- Hooshmand B, Azizi H, Javan M, and Semnani S (2017) Intra-LC microinjection of orexin type-1 receptor antagonist SB-334867 attenuates the expression of glutamate-induced opiate withdrawal like signs during the active phase in rats. *Neurosci Lett* **636**:276–281.
- Hooshmandi M, Hosseinmardi N, Janahmadi M, Khakpai F, Rohampour K, and Doostmohammadi J (2017) Antagonism of orexin type-1 receptors (OX1R) attenuates naloxone-precipitated morphine withdrawal syndrome in rat dorsal hippocampus. *Pharmacol Biochem Behav* **158**:39–48.
- Huhn AS, Berry MS, and Dunn KE (2018) Systematic review of sex-based differences in opioid-based effects. *Int Rev Psychiatry* **30**:107–116.
- Humphreys K and Saitz R (2019) Should physicians recommend replacing opioids with cannabis? *JAMA* **321**:639–640.
- Hutcheson DM, Everitt BJ, Robbins TW, and Dickinson A (2001) The role of withdrawal in heroin addiction: enhances reward or promotes avoidance? *Nat Neurosci* **4**:943–947.
- Jain K, Jain R, and Dhawan A (2011) A double-blind, double-dummy, randomized controlled study of meprobamate versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts. *J Opioid Manag* **7**:11–20.
- Jalal S, Daher E, and Hilu R (2013) A case of death due to ibogaine use for heroin addiction: case report. *Am J Addict* **22**:302 DOI: 10.1111/j.1521-0391.2012.00330.x.
- Jasinski DR (1981) Opiate withdrawal syndrome: acute and protracted aspects. *Ann N Y Acad Sci* **362**:183–186.
- Jicha CJ, Lofwall MR, Nuzzo PA, Babalonis S, Elayi SC, and Walsh SL (2015) Safety of oral dronabinol during opioid withdrawal in humans. *Drug Alcohol Depend* **157**: 179–183.
- Jones CM, Campopiano M, Baldwin G, and McCance-Katz E (2015) National and state treatment need and capacity for opioid agonist medication-assisted treatment. *Am J Public Health* **105**:e55–e63.
- Jovašša T, Laurinénas G, Vosylius S, Šipylaitė J, Badaras R, and Ivaškevičius J (2006) Effects of ketamine on precipitated opiate withdrawal. *Medicina (Kaunas)* **42**:625–634.
- Kang L, Wang D, Li B, Hu M, Zhang P, and Li J (2008) Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats. *Am J Drug Alcohol Abuse* **34**:541–552.
- Kathmann M, Flau K, Redmer A, Tränkle C, and Schlicker E (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. *Naunyn Schmiedeberg Arch Pharmacol* **372**:354–361.
- Khazan N and Colasanti B (1972) Protracted rebound in rapid movement sleep time and electroencephalogram voltage output in morphine-dependent rats upon withdrawal. *J Pharmacol Exp Ther* **183**:23–30.
- Kosten TA, DeCaprio JL, and Rosen MI (1995) The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. *Neuropsychopharmacology* **13**:323–333.
- Kotlinska J and Bochenki M (2007) Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice. *Eur J Pharmacol* **558**:113–118.
- Koyuncuoğlu H, Güngör M, Sağduyu H, and Arıcıoğlu F (1990) Suppression by ketamine and dextromethorphan of precipitated abstinence syndrome in rats. *Pharmacol Biochem Behav* **35**:829–832.
- Lalanne L, Nicot C, Lang JP, Bertschy G, and Salvat E (2016) Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: a case report. *BMC Psychiatry* **16**:395.
- Laorden ML, Ferenczi S, Pintér-Kübler B, González-Martín LL, Lasheras MC, Kovács KJ, Milanés MV, and Núñez C (2012) Hypothalamic orexin-A neurons are involved in the response of the brain stress system to morphine withdrawal. *PLoS One* **7**:e36871.
- Latowsky M (1996) Improving detoxification outcomes from methadone maintenance treatment: the interrelationship of affective states and protracted withdrawal. *J Psychoactive Drugs* **28**:251–257.
- Leal MB, Michelin K, Souza DO, and Elisabetsky E (2003) Ibogaine attenuation of morphine withdrawal in mice: role of glutamate N-methyl-D-aspartate receptors. *Prog Neuropsychopharmacol Biol Psychiatry* **27**:781–785.
- Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, et al. (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. *Lancet* **391**: 309–318.
- Leri F, Bruneau J, and Stewart J (2003) Understanding polydrug use: review of heroin and cocaine co-use. *Addiction* **98**:7–22.
- Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, and Hohmann AG (2019) Cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal. *Mol Pharmacol* **95**:155–168.
- Lichtman AH, Sheikh SM, Loh HH, and Martin BR (2001) Opioid and cannabinoid modulation of precipitated withdrawal in Δ⁹-tetrahydrocannabinol and morphine-dependent mice. *J Pharmacol Exp Ther* **298**:1007–1014.
- Lin SK, Chen CH, and Pan CH (2008) Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial. *J Clin Psychopharmacol* **28**:189–194.
- Lin SK, Pan CH, and Chen CH (2014) A double-blind, placebo-controlled trial of dextromethorphan combined with clonidine in the treatment of heroin withdrawal. *J Clin Psychopharmacol* **34**:508–512.
- Lofwall MR, Babalonis S, Nuzzo PA, Elayi SC, and Walsh SL (2016) Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. *Drug Alcohol Depend* **164**:143–150.
- Lu L, Su WJ, Yue W, Ge X, Su F, Pei G, and Ma L (2001) Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. *Life Sci* **69**:37–46.
- Mach RH, Smith CR, and Childers SR (1995) Ibogaine possesses a selective affinity for σ₂ receptors. *Life Sci* **57**:PL57–PL62.
- Malcolm BJ, Polanco M, and Barsuglia JP (2018) Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. *J Psychoactive Drugs* **50**:256–265.
- Malek A, Amiri S, and Habibi Asl B (2013) The therapeutic effect of adding dextromethorphan to clonidine for reducing symptoms of opioid withdrawal: a randomized clinical trial. *ISRN Psychiatry* **2013**:546030.
- Martin WR and Jasinski DR (1969) Physiological parameters of morphine dependence in man—tolerance, early abstinence, protracted abstinence. *J Psychiatr Res* **7**:9–17.
- Mash DC, Ameer B, Prou D, Howes JF, and Maillet EL (2016) Oral norbogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents. *J Psychopharmacol* **30**:688–697.
- Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, Roques BP, and Noble F (2001) Reduction of opioid dependence by the CB₁ antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. *Br J Pharmacol* **132**:1809–1816.
- Mazoyer C, Carlier J, Boucher A, Péoc'h M, Lemeur C, and Gaillard Y (2013) Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material. *J Forensic Sci* **58**:1666–1672.
- Medrano MC, Mendiguren A, and Pineda J (2015) Effect of ceftriaxone and topiramate treatments on naltrexone-precipitated morphine withdrawal and glutamate receptor desensitization in the rat locus coeruleus. *Psychopharmacology (Berl)* **232**:2795–2809.
- Mehtry V, Nizamie SH, Parvez N, and Pradhan N (2014) Sleep profile in opioid dependence: a polysomnographic case-control study. *J Clin Neurophysiol* **31**: 517–522.
- McKee SA (2009) Developing human laboratory models of smoking lapse behavior for medication screening. *Addict Biol* **14**:99–107.
- McKee SA, Weinberger AH, Shi J, Tetrault J, and Coppola S (2012) Developing and validating a human laboratory model to screen medications for smoking cessation. *Nicotine Tob Res* **14**:1362–1371.
- Negus SS and Banks ML (2018) Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: implications for negative reinforcement as a driver of addiction and target for medications development. *Pharmacol Biochem Behav* **164**:32–39.
- Niciu MJ, Kelmendi B, and Sanacora G (2012) Overview of glutamatergic neurotransmission in the nervous system. *Pharmacol Biochem Behav* **100**: 675–684.
- Northrup TF, Stotts AL, Green C, Potter JS, Marino EN, Walker R, Weiss RD, and Trivedi M (2015) Opioid withdrawal, craving, and use during and after

- outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. *Addict Behav* **41**:20–28.
- Obata H (2017) Analgesic mechanisms of antidepressants for neuropathic pain. *Int J Mol Sci* **18**:2483.
- Olsson M, Wall MM, Liu SM, and Blanco C (2018) Cannabis use and risk of prescription opioid use disorder in the United States. *Am J Psychiatry* **175**:47–53.
- Oyefeso A, Sedgwick P, and Ghodse H (1997) Subjective sleep-wake parameters in treatment-seeking opiate addicts. *Drug Alcohol Depend* **48**:9–16.
- Paling FP, Andrews LM, Valk GD, and Blom HJ (2012) Life-threatening complications of ibogaine: three case reports. *Neth J Med* **70**:422–424.
- Patucha-Poniewiera A, Novák K, and Pilc A (2009) Group III mGlu receptor agonist, ACPIT-1, attenuates morphine-withdrawal symptoms after peripheral administration in mice. *Prog Neuropsychopharmacol Biol Psychiatry* **33**:1454–1457.
- Panchal V, Taraschenko OD, Maisonneuve IM, and Glick SD (2005) Attenuation of morphine withdrawal signs by intracerebral administration of 18-methoxycoronaridine. *Eur J Pharmacol* **525**:98–104.
- Pang G, Wu X, Tao X, Mao R, Liu X, Zhang YM, Li G, Stackman RW Jr, Dong L, and Zhang G (2016) Blockade of serotonin 5-HT_{2A} receptors suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-treated mice. *Front Pharmacol* **7**:514.
- Parker LA and Siegel S (2001) Modulation of the effects of rewarding drugs by ibogaine. *Alkaloids Chem Biol* **56**:211–225.
- Pérez de los Cobos J, Duro P, Trujols J, Tejero A, Batlle F, Ribalta E, and Casas M (2001) Methadone tapering plus amantadine to detoxify heroin-dependent inpatients with or without an active cocaine use disorder: two randomised controlled trials. *Drug Alcohol Depend* **63**:187–195.
- Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KN, and Sparks GM (2013) Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. *Addiction* **108**:1962–1968.
- Perkins KA, Lerman C, Stitzer M, Fonte CA, Briski JL, Scott JA, and Chengappa KN (2008) Development of procedures for early screening of smoking cessation medications in humans. *Clin Pharmacol Ther* **84**:216–221.
- Pinelli A, Trivulzio S, and Tomasoni L (1997) Effects of ondansetron administration on opioid withdrawal syndrome observed in rats. *Eur J Pharmacol* **340**:111–119.
- Pinkofsky HB, Hahn AM, Campbell FA, Rueda J, Daley DC, and Douaihy AB (2005) Reduction of opioid-withdrawal symptoms with quetiapine. *J Clin Psychiatry* **66**:1285–1288.
- Powers BR (1949) Use of methadone to combat withdrawal symptoms of dilaudid addiction; case report. *J Tn State Med Assoc* **42**:83.
- Pozzi G, Conte G, and De Risio S (2000) Combined use of trazodone-naltrexone versus clonidine-naltrexone in rapid withdrawal from methadone treatment. A comparative inpatient study. *Drug Alcohol Depend* **59**:287–294.
- Preston KL, Sullivan JT, Strain EC, and Bigelow GE (1996) Enhancement of cocaine's abuse liability in methadone maintenance patients. *Psychopharmacology (Berl)* **123**:15–25.
- Quinlan J (2012) The use of a subanesthetic infusion of intravenous ketamine to allow withdrawal of medically prescribed opioids in people with chronic pain, opioid tolerance and hyperalgesia: outcome at 6 months. *Pain Med* **13**:1524–1525.
- Ramesh D, Gamage TF, Vanuysel T, Owens RA, Abdullah RA, Niphakis MJ, Shea-Donohue T, Cravatt BF, and Lichtman AH (2013) Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antinociceptive effects in morphine-dependent mice. *Neuropsychopharmacology* **38**:1039–1049.
- Rasmussen K, Kendrick WT, Kogan JH, and Aghajanian GK (1996) A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. *Neuropsychopharmacology* **15**:497–505.
- Rasmussen K, Martin H, Berger JE, and Seager MA (2005) The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. *Neuropharmacology* **48**:173–180.
- Rose JS, Branchey M, Wallach L, and Buydens-Branchey L (2003) Effects of buspirone in withdrawal from opiates. *Am J Addict* **12**:253–259.
- Rho B and Glick SD (1998) Effects of 18-methoxycoronaridine on acute signs of morphine withdrawal in rats. *Neuroreport* **9**:1283–1285.
- Romandini S, Cervo L, and Samanin R (1984) Evidence that drugs increasing 5-hydroxytryptamine transmission block jumping but not wet dog shakes in morphine-abstinent rats: a comparison with clonidine. *J Pharm Pharmacol* **36**:68–70.
- Rubino T, Massi P, Viganò D, Fuzio D, and Parolaro D (2000) Long-term treatment with SR141716A, the CB₁ receptor antagonist, influences morphine withdrawal syndrome. *Life Sci* **66**:2213–2219.
- Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* **92**:573–585.
- Samanin R, Cervo L, Rochat C, Poggesi E, and Mennini T (1980) Reduction in the number of serotonin receptors in the brainstem of morphine dependent rats: relation to blockade of naloxone precipitated jumping by serotonin agonists. *Life Sci* **27**:1141–1146.
- Schreiber S, Backler MM, Herman I, Shamir D, Rigai T, Bar-Hamburger R, and Pick CG (2003) Mianserin and trazodone significantly attenuate the intensity of opioid withdrawal symptoms in mice. *Addict Biol* **8**:107–114.
- Schuckit MA (2016) Treatment of opioid-use disorders. *N Engl J Med* **375**:357–368.
- Schulz R and Herz A (1977) Naloxone-precipitated withdrawal reveals sensitization to neurotransmitters in morphine tolerant/dependent rats. *Naunyn Schmiedeberg Arch Pharmacol* **299**:95–99.
- Sekiya Y, Nakagawa T, Ozawa T, Minami M, and Satoh M (2004) Facilitation of morphine withdrawal symptoms and morphine-induced conditioned place preference by a glutamate transporter inhibitor DL-threo-β-benzyloxyaspartate in rats. *Eur J Pharmacol* **485**:201–210.
- Shahidi S and Hasanein P (2011) Behavioral effects of fatty acid amide hydrolase inhibition on morphine withdrawal symptoms. *Brain Res Bull* **86**:118–122.
- Shahidi S and Hashemi-Firouzi N (2014) The effects of a 5-HT₇ receptor agonist and antagonist on morphine withdrawal syndrome in mice. *Neurosci Lett* **578**:27–32.
- Sharf R, Sarhan M, and Dileone RJ (2008) Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. *Biol Psychiatry* **64**:175–183.
- Sharpe LG and Jaffe JH (1990) Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat. *Neuroreport* **1**:17–19.
- Sheppard SG (1994) A preliminary investigation of ibogaine: case reports and recommendations for further study. *J Subst Abuse Treat* **11**:379–385.
- Srisuranont M and Jarusuraisin N (1998) Amitriptyline vs. lorazepam in the treatment of opiate-withdrawal insomnia: a randomized double-blind study. *Acta Psychiatr Scand* **97**:233–235.
- Streeb E, Dan B, Antoniali V, Clement B, Campanella S, Hanak C, Vanderlinden P, Pele I, and Verbanck P (2005) Effects of anaesthetic agents in interference of naloxone-induced opiate-withdrawal are dose-dependent in opiate-dependent rats. *Life Sci* **77**:650–655.
- Strickler EM, Schwenk ES, Cohen MJ, and Viscusi ER (2018) Use of ketamine in a multimodal analgesia setting for rapid opioid tapering in a profoundly opioid-tolerant patient: a case report. *A A Pract* **10**:179–181.
- Tanganelli S, Antonelli T, Morari M, Bianchi C, and Beani L (1991) Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs. *Neurosci Lett* **122**:270–272.
- Tanum L, Solli KK, Latif ZE, Benth JS, Opheim A, Sharma-Haase K, Krajci P, and Kunøe N (2017) Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical non-inferiority trial. *JAMA Psychiatry* **74**:1197–1205.
- Tokuyama S, Wakabayashi H, and Ho IK (1996) Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. *Eur J Pharmacol* **295**:123–129.
- Tokuyama S, Zhu H, Wakabayashi H, Feng YZ, and Ho IK (1998) The role of glutamate in the locus coeruleus during opioid withdrawal and effects of H-7, a protein kinase inhibitor, on the action of glutamate in rats. *J Biomed Sci* **5**:45–53.
- Vandergriff J and Rasmussen K (1999) The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. *Neuropharmacology* **38**:217–222.
- van Dongen PA (1981) The central noradrenergic transmission and the locus coeruleus: a review of the data, and their implications for neurotransmission and neuromodulation. *Prog Neurobiol* **16**:117–143.
- Vela G, Ruiz-Gayo M, and Fuentes JA (1995) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. *Neuropharmacology* **34**:665–668.
- Volkow ND, Wise RA, and Baler R (2017) The dopamine motive system: implications for drug and food addiction. *Nat Rev Neurosci* **18**:741–752.
- Vocci F and Ling W (2005) Medications development: successes and challenges. *Pharmacol Ther* **108**:94–108.
- Wakim JH (2012) Alleviating symptoms of withdrawal from an opioid. *Pain Ther* **1**:4.
- Wang C, Wang Q, Ji B, Pan Y, Xu C, Cheng B, Bai B, and Chen J (2018) The orexin/receptor system: molecular mechanism and therapeutic potential for neurological diseases. *Front Mol Neurosci* **11**:220.
- Warden D, Subramaniam GA, Carmody T, Woody GE, Minhajuddin A, Poole SA, Potter J, Fishman M, Bogenschutz M, Patkar A, et al. (2012) Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. *Addict Behav* **37**:1046–1053.
- Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, and Satoh M (2002) Involvement of glutamate receptors within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. *Jpn J Pharmacol* **88**:399–406.
- Wesson DR and Ling W (2003) The clinical opiate withdrawal scale (COWS). *J Psychoactive Drugs* **35**:253–259.
- Wu X, Pang G, Zhang YM, Li G, Xu S, Dong L, Stackman RW Jr, and Zhang G (2015) Activation of serotonin 5-HT_{2C} receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in heroin-treated mice. *Neurosci Lett* **607**:23–28.
- Zhang G, Wu X, Zhang YM, Liu H, Jiang Q, Pang G, Tao X, Dong L, and Stackman RW Jr (2016) Activation of serotonin 5-HT_{2C} receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice. *Neuropharmacology* **101**:246–254.
- Zullino DF, Cottier AC, and Besson J (2002) Topiramate in opiate withdrawal. *Prog Neuropsychopharmacol Biol Psychiatry* **26**:1221–1223.
- Zullino DF, Khazaal Y, Hättenschwiler J, Borgeat F, and Besson J (2004) Anticonvulsant drugs in the treatment of substance withdrawal. *Drugs Today (Barc)* **40**:603–619.

Address correspondence to: Dr. Kelly E. Dunn, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224. E-mail: kdunn9@jhmi.edu